



(51) International Patent Classification:

A61K 38/21 (2006.01) A61K 31/52 (2006.01)
C07K 14/555 (2006.01) A61P 35/00 (2006.01)
C07K 14/715 (2006.01)

(21) International Application Number:

PCT/SG2013/000490

(22) International Filing Date:

19 November 2013 (19.11.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201208522-1 19 November 2012 (19.11.2012) SG

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG).

(72) Inventors: YU, Qiang; 60 Biopolis Street #02-01, Singapore 138672 (SG). WEE, Zhen Ning; 60 Biopolis Street #02-01, Singapore 138672 (SG).

(74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))



WO 2014/077784 A1

(54) Title: METHOD OF TREATING CANCER

(57) Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.

METHOD OF TREATING CANCER

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of Singapore provisional patent application No. 201208522-1, filed November 19, 2012, the contents of it being hereby
5 incorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

[0002] The present invention relates to pharmaceutical compositions and methods for
10 treating cancer. The present invention further relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers and also provides novel markers useful for the diagnosis, characterization, and treatment of cancers.

BACKGROUND OF THE INVENTION

15 [0003] While hormonal therapy has been largely successful in the management of cancer patients in their early stages, the disease often progresses to metastatic disease which is hormone refractory and resistant to existing treatments. There is currently no optimal treatment that can slow down the disease progression in patients with metastatic disease.

[0004] For example, in patient with advanced prostate tumours, the current treatment
20 include surgical treatments such as radical prostatectomy (RP), in which the prostate is completely removed (with or without nerve sparing techniques) and radiation or chemotherapy. Hormone therapy such as anti-androgen therapy is also used, alone or in conjunction with surgery or radiation. IFN- γ is an example of anti-tumour agent that has been used to treat cancers, including prostate and breast cancer but with limited success. Hence,
25 while hormonal and surgical treatments are often effective for localized prostate cancer, advanced disease is often refractory to such treatments and thus, incurable.

[0005] Treatment of cancer can be more efficient if some early genetic markers are identified that allow adapted treatments that would allow the use of smaller amounts of chemotherapeutic agents and restoration of normal cell function. In addition, much effort has
30 been expended to identify genetic determinants in patient outcomes, so as to improve clinical treatment decisions and for the design of therapeutic agents. To date, no known genetic

markers have been reported, that could help determine the dose and clinical outcomes in patients receiving anti-cancer treatments.

[0006] Recent introduction of targeted therapy and increasing numbers of available chemotherapeutic regimens, such as platinum and derivatives, taxanes and gemcitabine, do not effectively cure cancer patients, with varied response towards treatment and occurrence of drug toxicity. In addition, prognosis remains dismal in advanced cancer patients albeit careful evaluation of clinico-pathological factors that determine patient response to therapy, such as tumor, nodes and metastasis (TNM) staging, performance status, gender and weight loss.

[0007] Accordingly, there is a need for developing new therapeutic targets and pharmaceutical compositions for the treatment of cancer patients.

SUMMARY OF THE INVENTION

[0008] In a first aspect, the present invention provides a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity.

[0009] In a second aspect, the present invention provides a method of treating a patient having cancer comprising administration of the pharmaceutical composition as defined herein.

[0010] In a third aspect, the present invention provides a method for determining susceptibility of a patient suffering from cancer to a treatment with a pharmaceutical composition as defined herein, wherein the method comprises, comparing a first level of EZH2 comprising but not limited to EZH2 mRNA level in a tumor sample, EZH2 cDNA level made from mRNA from said tumor sample, and EZH2 protein level from said tumor sample, with a second level of EZH2 comprising but not limited to EZH2 mRNA level from a non-tumor sample from said patient, EZH2 cDNA level made from mRNA from said non-tumor sample, and EZH2 protein level from said non-tumor sample; comparing a first level of IFNGR1 comprising but not limited to IFNGR1 mRNA level from said tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1 comprising but not limited to IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample;

and wherein a patient characterized by an increased level of EZH2 in said tumor sample and a decreased level of IFNGR1 in said tumor sample is susceptible to a treatment with said pharmaceutical composition.

[0011] In a fourth aspect, the present invention provides a method for treating cancer in a patient with a difference in the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein in a tumor sample, and the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein from a non-tumor sample, wherein the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein are at least 2-fold higher in the tumor sample and the IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein level is at least 2-fold lower in the tumor sample, wherein the method comprises administration of a pharmaceutical composition as defined herein to the patient.

[0012] In a fifth aspect, disclosed herein is a method for determining susceptibility of a patient suffering from advanced prostate cancer to a treatment with a pharmaceutical composition as defined herein, wherein the method comprises comparing a first level of IFNGR1 comprising but not limited to IFNGR1 mRNA level in a tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1 comprising but not limited to IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample; and wherein a patient characterized by a decreased level of IFNGR1 in said tumor sample is susceptible to a treatment with said pharmaceutical composition.

[0013] In a sixth aspect, disclosed herein is a method for determining susceptibility of a patient suffering from breast cancer to a treatment with a pharmaceutical composition as defined herein, wherein the method comprises comparing a first level of IFNGR1 comprising but not limited to IFNGR1 mRNA level in a tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1 selected from the group consisting of IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample wherein a patient suffering from basal breast cancer is characterized by an increased level of IFNGR1 in said tumor sample is not susceptible to a treatment with said pharmaceutical composition and

wherein a patient suffering from luminal breast cancer is characterized by a decreased level of IFNGR1 in said tumor sample is susceptible to a treatment with said pharmaceutical composition.

[0014] In a seventh aspect, disclosed herein is a method for making a prognosis with respect to the clinical outcome of a patient suffering from cancer comprising comparing a first level of EZH2 comprising but not limited to EZH2 mRNA level in a tumor sample, EZH2 cDNA level made from mRNA from said tumor sample, and EZH2 protein level from said tumor sample, with a second level of EZH2 comprising but not limited to EZH2 mRNA level from a non-tumor sample from said patient, EZH2 cDNA level made from mRNA from said non-tumor sample, and EZH2 protein level from said non-tumor sample, comparing a first level of IFNGR1 comprising but not limited to IFNGR1 mRNA level from said tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1 comprising but not limited to IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample and making a prognosis with respect to the clinical outcome of a patient suffering from cancer.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which:

[0016] **Figure 1** is a series of drawings, graphs and western-blot analysis showing that oncogenic transformation by MYC and PI3K induced transcriptional inactivation of IFN- γ -JAK-STAT1 signaling pathway.

[0017] Figure 1(A) is an unsupervised hierarchical clustering showing 610 genes that were differentially regulated in either RWPE1-MYC and RWPE1-PI3K cells compared to RWPE1-vector control cells (2-fold cutoff, $P < 0.01$) The colored scale bar represents the absolute fold change.

[0018] Figure 1(B) is a table summarizing an Ingenuity Pathway Analysis (IPA) that shows interferon signaling pathway as the top gene network enriched in downregulated genes in transformed RWPE1 cells.

[0019] Figure 1(C) is a Venn diagram (not drawn to scale) showing the overlapping of genes downregulated in RWPE1-MYC and RWPE1-PI3K cells with known IFN genes in the INTERFEROME database.

[0020] Figure 1(D) is a graphical depiction of representative IFN genes in the IFN-JAK-STAT1 pathway. Shadowed molecules represent the genes that were downregulated in RWPE1-MYC and RWPE1-PI3K cells.

[0021] Figure 1(E) is a bar graph plotting the values of an ELISA assay. Figure 1E shows JAK2 phosphorylation and activation in RWPE cells treated with or without IFN- γ treatment. The Y1007/1008 phosphorylation level of JAK2 was normalized and expressed fold change against the total JAK2 level. Sensitivity to IFN- γ was determined by comparing the phosphorylation status of JAK2 between IFN- γ treated and untreated control cells.

[0022] Figure 1(F) is a graph summarizing the STAT1-driven luciferase reporter activity of indicated RWPE1 cell lines treated with or without IFN- γ .

[0023] Figure 1(G) is a series of western blots showing the IFNGR1 and STAT1 phosphorylation in RWPE1 cell lines treated with or without 25ng/mL of IFN- γ .

[0024] Figures 1(H) and 1(I) are a pair of graphs depicting qRT-PCR analysis of IFNGR1 and multiple IFN genes in RWPE1-MYC and RWPE1-PI3K cells as well as (I) prostate cancer cell lines normalized to RWPE1 control counterparts. All the data in the graph bars represent mean + Standard error of the mean (or measurement; (SEM)), n=3. ** p<0.01, ***p<0.001, n.s.=not significant.

[0025] **Figure 2** is a series of graphs and analysis showing that IFNGR1 is a direct target of EZH2 in MYC-driven, but not PI3K-driven prostate cancer cells.

[0026] Figure 2(A) is a graph showing qRT-PCR analysis of IFNGR1 and other IFN genes upon ectopic EZH2 expression in RWPE1 cells.

[0027] Figure 2(B) is a pair of bar graphs showing a qRT-PCR analysis demonstrating the restoration of IFNGR1 expression, but not IFNAR1, following *EZH2* knockdown in RWPE1-MYC cells but not in RWPE1-PI3K cells.

[0028] Figure 2 (C) is a western blot validating the overexpression of c-MYC, constitutive active mutant of PI3K and phosphorylation status of AKT and EZH2 in RWPE1 cell lines treated with or without 25ng/mL of IFN- γ .

[0029] Figure2 (D) is a schematic drawing showing the ChIP primer locations with respect to the transcriptional start site (TSS) of the IFNGR1 promoter.

[0030] Figure 2 (E) is a series of histogram plots of ChIP analysis showing the enrichment of EZH2 at the promoter of IFNGR1 in transformed cell lines as indicated. The fold enrichments over IgG control further normalized to the actin promoter are shown. EZH2 known target CNR promoter was used as a positive control.

5 [0031] Figure 2(F) is a series of graphs of ChIP analysis showing EZH2 enrichment at the promoter of IFNGR1 in indicated prostate cancer cell lines.

[0032] Figure 2(G) is a pair of bar graphs of ChIP analysis showing the enrichment of EZH2 and H3K27me3 in the IFNGR1 promoter in DU145 and LNCaP cells before and after MYC knockdown. All the data in the graph bars represent mean +SEM, n=3. *p<0.05, **p<0.01, ***p<0.001, n.s.=not significant.

[0033] Figure 3 is a series of scatter plots and immunohistochemistry images showing the inverse relationship between MYC/EZH2 and IFNGR1 expression levels in advanced prostate cancer.

[0034] Figure 3(A) is a series of scatter plots showing the mRNA expression (Log2) of EZH2, MYC, IFNGR1 and IFN- γ responsive genes (MX1, IRF1 and IFI16) to compare between Metastatic (n=35) and localized Prostate tumors (n=59) with normal prostate tissue (n=28) from the Grasso Prostate dataset (**p<0.01, ***p<0.001).

[0035] Figure 3(B) is a series of scatter plots showing the mRNA expression (Log2) of IFNGR1 (left) and EZH2 (right) after stratifying all prostate cancer tumors in the Grasso Prostate dataset according to their MYC expression. Prostate tumors with MYC expression higher than its median level were categorized as the "Hi-MYC" group (n=59) and vice versa for the "Low-MYC" group (n=61). This analysis excludes the normal prostate tissue. (*p<0.05, ***p<0.001).

[0036] Figure 3(C) is a series of representative images of the prostate cancer TMA-IHC staining showing the downregulation of IFNGR1 in metastatic and advanced prostate cancer tumors with high levels of EZH2 and MYC. Scale bars= 100 μ m.

[0037] Figure 4 is a series of graphs and western blots showing that MYC/EZH2-mediated inactivation of IFN γ -JAK-STAT1 signaling confers growth and survival advantages.

30 [0038] Figure 4(A) is a series of graphs of qRT-PCR analysis of three IFN responsive genes, MX1, IRF1 and IFI16 in DU145, PC3, LNCaP and 22RV1 cells. The indicated cells

lines where treated with siRNA to knockdown EZH2 expression and treated with the indicated amount of IFN- γ afterwards.

[0039] Figure 4(B) is a series of western blot analysis of IFNGR1 expression and IFN- γ signaling upon EZH2 knockdown in the presence of IFN- γ at the doses indicated (0, 5 and 25 ng/ml).

[0040] Figure 4(C) is a bar graph of an ELISA assay showing JAK2 phosphorylation and activation in DU145 cells treated with siEZH2, IFN- γ (25ng/mL) or both. The Y1007/1008 phosphorylation level of JAK2 was normalized and expressed as fold change against the total JAK2 level.

10 [0041] Figure 4(D) is a series of western blot analysis of IFNGR1 expression and IFN- γ signaling upon MYC knockdown in the presence of IFN- γ at indicted doses.

[0042] Figure 4(E) is a series of scatter plots of cell proliferation assay in DU145 and LNCaP cells treated with either siRNA against MYC (siMYC) or EZH2 (siEZH2) in combination with IFN- γ . The proliferation of the cells are represented as fold change after normalizing to the baseline Cell Titer Glow (CTG) signal on Day 0 (T_0).

15 [0043] Figure 4(F) is a pair of histogram plots of sub-G1 (apoptosis) by FACS analysis. *Left*, Sub-G1 DNA assessment by FACS in DU145 cells treated with siEZH2 or siMYC together with IFN- γ , in the presence or absence of CD119 a neutralizing antibody that blocks the binding of the activating ligand, IFN- γ to its receptor, IFNGR1. This prevents the activation of the IFN- γ signaling pathway. Hence, Figure 4(F) shows that inhibition of EZH2 specifically enhances IFN- γ mediated cell death. *Right*, Sub-G1 DNA analysis by FACS in LNCaP cells treated with siMYC or siEZH2 in combination with IFN- γ .

[0044] Figure 4(G) is a series of histogram plots and microscopy images of prostatospheres formation assays. *Left*, Prostatosphere formation assay after treating DU145, PC3, LNCaP and 22RV1 with either IFN- γ , siEZH2 or both for 7 days. *Right*, representative phase contrast microscopy images of the prostatospheres taken at 10x magnification after treatment with siEZH2 and IFN- γ (25ng/mL).

[0045] All the data in the graph bars represent mean +SEM, n=3. *p<0.05, ** p<0.01, ***p<0.001, n.s=not significant.

30 [0046] **Figure 5** is a series of graphs and western blots demonstrating that DZNep mimics EZH2 knockdown and is capable of restoring IFN- γ response to induce growth inhibition and apoptosis.

[0047] Figure 5(A) is a series of histogram plots of quantitative PCR showing the increase in gene expression of IFNGR1 and various IFN responsive genes but not IFNAR1 after 72 hr of DZNep treatment (2.5 μ M) as well as IFN γ treatment at indicated doses.

[0048] Figure 5(B) is a series of western blot analysis of IFNGR1 expression and IFN- γ signaling in DU145 cells treated with DZNep (2.5 μ M), IFN- γ at the indicated concentration or both for 3 days.

[0049] Figure 5(C) is a histogram plot of a FACS sub-G1 DNA analysis in DU145 and LNCaP cells treated as (B).

[0050] Figure 5(D) is a histogram plot of a FACS sub-G1 DNA analysis in DU145 cells treated with DZNep/IFN- γ as above in the presence or absence of IFNGR1 neutralizing antibody CD119 at indicated concentrations.

[0051] Figure 5(E) is a series of western blot analysis of EZH2, IFN signaling and PARP cleavage in DU145 cells treated with DZNep/IFN- γ with similar conditions as (D).

[0052] Figure 5(F) is a series of scatter plots showing cell proliferation assay of MYC-dependent cell lines (DU145 and PC3) and MYC-independent cell lines (LNCaP and 22RV1) after treatment with either IFN- γ , DZNep or both for days as indicated. The proliferation of the cells are represented as fold change after normalizing to the baseline Cell Titer Glow (CTG) signal on Day 0 (T0).

[0053] Figure 5(G) is a pair of histogram plots and representative phase contrast microscopy images of the prostatospheres formation assays. Left, prostatosphere formation assay showing the effectiveness of combining low doses of DZNep with IFN γ to inhibit the formation of prostatospheres in indicated cell lines. Right, representative phase contrast microscopy images of the prostatospheres of DU145 and PC3 taken at 10x magnification after treatment with DZNep (0.5 μ M) and IFN- γ (25ng/mL).

[0054] All the data in the graph bars represent mean \pm SEM, n=3. *p<0.05, ** p<0.01, ***p<0.001, n.s.=not significant. is a series of micrographs and a pair of bar graphs showing that the DZNep and IFN- γ combination significantly reduces the quantity and size of prostatospheres. The quantification of the prostatospheres was done with the Gelcount colony counter. The minimum size for prostatospheres derived from DU145 to be considered positive was set at 120 μ M. (The cut-off varies from cell line to cell line and it is largely dependent on the proliferation rate of the cell lines as well as the length of the experiment.

[0055] **Figure 6** is a pair of scatter plots and immunohistochemistry staining images showing combinatorial anti-tumour effect of DZNep and IFN- γ *in vivo*.

[0056] Figure 6(A) is a scatter plot showing DU145 xenograft tumor growth in male athymic nude mice treated with vehicle (n=5), IFN- γ (1×10^7 IU/kg, intraperitoneally (i.p.) n=6), DZNep (1 mg/kg, subcutaneously (s.c.) n=7) or both (n=8). Thus Figure 6(A) is a graph establishing that a composition comprising DZNep and IFN- γ shows a synergistic effect *in vivo* in its ability to shrink or stabilize the volume of a tumour resulting from the xenograft of DU145 in mice. Mean tumor volume \pm s.e.m. is shown ***p<0.001.

[0057] Figure 6(B) is a scatter plot showing the body weight change (\pm s.e.m) of the mice during the drug treatment as indicated above.

[0058] Figure 6(C) is a series of images of immunohistochemistry analysis of EZH2 and IFNGR1 expression in tissue sections taken from DU145 xenograft tumors after the treatment as described in Figure 6(A).

[0059] **Figure 7** is a series of analysis showing that catalytic inhibitors of EZH2 fail to recapitulate the EZH2 knockdown effects.

[0060] Figure 7(A) is a series of western blot analysis of IFNGR1, PRC2 proteins and H3K27me3 in DU145 cells treated with DZNep, GSK343, or GSK126 at indicated doses for 3 or 10 days.

[0061] Figure 7(B) is a histogram plot of qRT-PCR analysis of *IFNGR1* expression in DU145 cells treated with indicated drugs for 3 or 10 days.

[0062] Figure 7(C) is a histogram plot of ChIP analysis of EZH2 and H3K27me3 enrichments at *IFNGR1* in DU145 cells treated with either DMSO, DZNep (2.5 μ M) or GSK126 (5 μ M) for 3 days. Enrichments were expressed as percentage of total input used for chromatin immuno-precipitation.

[0063] Figure 7(D) is a histogram plot of a FACS sub-G1 DNA analysis in DU145 cells treated with DZNep, or GSK343/GSK126, in combination with IFN- γ as indicated.

[0064] Figure 7(E) is a histogram plot of prostatosphere formation assay after treating DU145 cells with IFN- γ (25ng/mL) and GSK126 for 10 days at doses as indicated.

[0065] Figure 7(F) is a schematic cartoon model showing EZH2-mediated inactivation of IFN-JAK-STAT1 signaling regulated by MYC and PI3K-AKT. MYC overexpression leads to EZH2 activation through antagonizing miR-26a and PI3K-AKT-mediated EZH2 inhibition, resulting in suppression of *IFNGR1* and the downstream JAK-STAT1 signaling.

DZNep depletion of EZH2/PRC2 restores *IFNGR1* expression and synergizes with IFN- γ to induce growth inhibition and apoptosis.

[0066] All the data in the graph bars represent mean \pm SEM, n=3. *p<0.05, ** p<0.01, n.s. = not significant.

5 [0067] **Figure 8** is a graph and immunofluorescence and contrast microscope images validating the transformation induced by MYC and activated PI3K mutant in RWPE1 benign prostate epithelial cell line. On the top left corner is a histogram plot of a soft agar assay showing significant difference (*p<0.05) in anchorage independent growth of RWPE1-MYC and RWPE1-PI3K in comparison to RWPE1-Vector. Representative scanned image of the
10 soft agar colonies (left), Phase-contrast microscopy image of the soft agar colonies taken at 4x magnification (top right), GFP fluorescent microscopy image of the soft agar colonies taken at 4x magnification (bottom right) showing the specificity of the overexpression.

[0068] **Figure 9** is a series of graphs showing Myc overexpression in relation to miR-26a and EZH2 expression and the stratification of prostate cancer cells according to MYC
15 dependency.

[0069] Figure 9(A) is a pair of histogram plots of quantitative PCR analysis showing the reduction of endogenous microRNA miR-26a (left) expression in Myc overexpressing RWPE1 cells but not in miR-26b expression (right).

[0070] Figure 9(B) is a pair of histogram plots of quantitative PCR analysis validating the
20 over expression of Myc in RWPE1 cells that were infected with the retrovirally infected cells (left) and corresponding increase in EZH2 transcriptional expression (right).

[0071] Figure 9(C) is a series of histogram plots of ChIP followed by qPCR indicating insignificant enrichment of EZH2 on promoters of various IFN- γ pathway activated genes in RWPE1-MYC, RWPE1-PI3K and RWPE1-Vector cells. Thus Figure 9(C) indicates that
25 downregulation of downstream IFN signaling genes is due to the EZH2-mediated repression of the IFN gamma receptor (*IFNGR1*) and that EZH2 do not affect other downstream IFN signaling genes.

[0072] Figure 9(D) is a series of scatter plot of Cell Titer Glo proliferation assay measuring the growth of DU145, PC3, 22RV1 and LNCaP cells over 6 days in the presence
30 or absence of siRNA against *MYC* expression. The growth of these cells was normalized and plotted as fold change against the Cell Titer Glo (CTG) signal on Day 0 (T_0).

[0073] Figure 9(E) is a series of images of Methylation Specific PCR (MSP) analysis of IFNGR1 promoter in RWPE1 sub-lines and prostate cancer cell lines showing DNA methylation in LNCaP and RWPE1-PI3K cells but not in DU145 and RWPE1-Myc cells. (U is unmethylated promoter, M is methylated).

5 [0074] **Figure 10** is a series of graphs the effects of DZNep on apoptosis and IFN- γ stimulation.

[0075] Figure 10(A) is a graph of FACS analysis demonstrating the synergistic effect between DZNep (2.5 μ M) and IFN- γ to specifically induce cell death in RWPE1-MYC cells but not RWPE1-PI3K cells. Cells were treated with either DMSO or DZNep (2.5 μ M) for 3
10 days with increasing doses of IFN- γ . **p<0.01, n.s.=not significant

[0076] Figure 10(B) is a graph of FACS analysis showing the synergistic induction of cell death in DU145 cells when DZNep (2.5 μ M) was added in combination with IFN- γ but was not observed in other epigenetic inhibitors.

[0077] Figure 10(C) is a graph showing a FACS-derived sub-G1 DNA analysis in DU145
15 cells treated with DZNep/IFN- γ in the presence or absence of JAK2 inhibitor Axon 1588.

[0078] Figure 10(D) is a series of histogram plots of quantitative PCR analysis showing the enhanced response to IFN- γ stimulation after DZNep treatment as reflected by the up-regulation of IFN responsive genes, IFI16, IRF1 and OAS1 in DU145 cells but not LNCaP cells derived prostatospheres.

20 [0079] **Figure 11** is a series of heatmaps and graphs showing the inverse relationship between EZH2 and IFNGR1 expression observed in multiple human cancers, including MYC driven Burkitt's lymphoma.

[0080] Figure 11(A) is a table summarizing of an oncomine analysis showing the upregulation of EZH2 was companied by the down regulation of IFNGR1 in many datasets of
25 different cancer types.

[0081] Figure 11(B) is a series of dot plots showing the mRNA expression (Log2) of EZH2, MYC, IFNGR1 and IFN responsive genes (IRF1 and IFI35) in lymphoma tumors with or without Ig-MYC fusion extracted from the Hummel Lymphoma dataset (**p<0.01, ***p<0.001, n.s.= not significant, unpaired two tailed student's t-test).

30 [0082] Figure 11(C) is a heatmap representation showing the inverse correlation between mRNA expression of EZH2, MYC and IFNGR1 in various subtypes of Lymphoma tumors extracted from the Basso Lymphoma dataset.

[0083] **Figure 12** is a series of graphs, western blots and IHC analysis showing how EZH2 represses IFNGR1 expression in luminal breast cancer.

[0084] Figure 12(A) is a pair of box plots generated from GOBO analysis on a panel of breast cancer cell lines illustrating that the IFNGR1 expression is significantly lower in luminal and ER+ breast cancer cell lines as compared to other subtypes of breast cancer cell lines.

[0085] Figure 12(B) is a pair of box plots generated from GOBO analysis showing the mRNA expression (Log2) of IFNGR1 (left) and EZH2 (right) in a dataset containing 1881 breast tumor samples which were further categorized according to their molecular subtype.

Error bars, mean \pm s.e.m.

[0086] Figure 12(C) is a series of western blot analysis of IFNGR1 and EZH2 expression in a panel of luminal and basal-like breast cancer cell lines.

[0087] Figure 12(D) is a series of representative IHC imaging showing IFNGR1 and EZH2 expression in ER+ and ER- breast tumors. Coordinates of the tumor samples in the TMA slide were as indicated in parentheses. Scale bar = 100 μ m.

[0088] Figure 12(E) is a pair of Kaplan-Meier analysis of distant metastasis free survival (DMFS) of breast cancer patients with low (Grey), intermediate (Red) or high (Blue) level of IFNGR1 expression in ER+ vs. ER- tumors.

[0089] Figure 12(F) is a graph and western blot showing (Left) qRT-PCR analysis of IFNGR1 mRNA in MCF7 and MB231 cells treated with siEZH2 (*p<0.05) and (right) western blotting of IFNGR1 and EZH2 in MCF-7 cells treated with siEZH2 or DZNep.

[0090] Figure 12(G) is a histogram plot of a ChIP analysis using EZH2 and H3K27me3 enrichments in the IFNGR1 promoter in MCF7 and MB231 cells. The enrichment is expressed as a percentage of the total DNA input.

[0091] Figure 12(H) is a graph of a FACS generated sub-G1 DNA analysis of a panel of breast cancer cell lines treated with DZNep in combination with IFN- γ as indicated.

[0092] Figure 12(I) is a series of western blotting analysis of the indicated proteins in MCF7 and T47D cells treated with the indicated amount of DZNep, IFN- γ , or a combination of both. DMSO was used as a solvent and thus is used as a negative control.

[0093] **Figure 13** is a series of box plots, IHC images and graphs demonstrating EZH2-mediated downregulation of *IFNGR1* in liver cancer.

[0094] Figure 13 A and B are a pair of dot plots generated after quantifying the intensity of immunochemical staining of liver cancer tissue microarray (TMA) illustrating the inverse correlation between the protein expression (A) IFNGR1 and (B) EZH2 in liver cancer tumors as the disease progresses in clinical grade. (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, n.s. = not significant, two-tailed student's t-test).

[0095] Figure 13(C) is a series of representative images of immune-histochemical staining of liver cancer tissue microarray (TMA) used to generate the plots described above. Representative images of the liver cancer TMA-IHC staining (20x magnification) showing the downregulation of IFNGR1 in liver cancer tumors with different clinical grading. Scale bars= 100 μ M.

[0096] Figure 13(D) is a western blotting analysis showing the inverse correlation between protein expression level of IFNGR1 and EZH2 in a panel of liver cancer cell lines with high expression of EZH2.

[0097] Figure 13(E) is a graph of a FACS generated sub-G1 DNA analysis of a panel of liver cancer cell lines treated with DZNep alone or in combination with IFN- γ as indicated. The FACS analysis illustrates the synergistic effect between DZNep and IFN- γ to induce robust cell death in several liver cancer cell lines.

[0098] **Figure 14** is a series of scatter plots, western blots and IHC demonstrating EZH2-mediated downregulation of IFNGR1 in lung cancer.

[0099] Figure 14(A, B & C) is a series of scatter plots generated after quantifying the intensity of immunochemical staining of liver cancer tissue microarray (TMA) illustrating the inverse correlation between the protein expression (A) IFNGR1, (B) EZH2 and (C) MYC in different subtypes of lung cancer tumors. (** $p < 0.01$, *** $p < 0.001$, n.s.=not significant, two-tailed student's t-test)

[00100] Figure 14(D) is a western blotting analysis showing the inversely related protein expression of IFNGR1 and EZH2 in a panel of lung cancer cell lines.

[00101] Figure 14(E) is a pair of box plots generated from the oncomine analysis of the Bhattacharjee lung dataset showing that upregulation of (right) EZH2 is accompanied by the down regulation of (left) IFNGR1, particularly so in small cell lung cancer tumors.

[00102] Figure 14(F) is a histogram plot generated from a FACS analysis of sub-G1 contents illustrating the synergistic effect between DZNep and IFN- γ to induce robust cell death in several lung cancer cell lines.

[00103] Figure 14(G) is a series of representative images of lung cancer TMA-IHC staining showing downregulation of IFNGR1 in small cell lung cancer tumors with high levels of EZH2 and MYC protein expression. Scale bars= 100 μ M.

5 [00104] Figure 14(H) is a series of representative images of lung cancer TMA-IHC staining showing the downregulation of IFNGR1 in metastatic lung cancer with high levels of EZH2 and MYC. Scale bars= 100 μ M.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

10 [00105] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including", "containing", etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.

15 [00106] As used herein, the singular form "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "an agent" includes a plurality of agents, including mixtures thereof and reference to "the nucleic acid sequence" generally includes reference to one or more nucleic acid sequences and equivalents thereof known to those skilled in the art, and so forth.

20 [00107] As used herein, the term "comprising" means "including". Thus, for example, a composition "comprising" X may consist exclusively of X or may include one or more additional components.

30 [00108] The invention has been described broadly and generically herein. Each of the narrower species and sub-generic groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or

negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[00109] Other embodiments are within the following claims and non-limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[00110] The present disclosure relates to pharmaceutical compositions and therapies for cancer, such as for example, prostate cancer, breast cancer including but not limited to luminal B breast cancer, liver cancer, ovarian cancer, acute lymphoblastic leukemia (ALL).

[00111] During development, a cell's fate is decided by the initial gene expression. After acquiring its fate and position, this cellular identity is maintained by keeping some genes "on" and others "off". This transcriptional "memory" if perturbed can lead to severe developmental defects. If the maintenance mechanism fails, cells may lose their capacities of proliferation, differentiation, adhesion or invasion. Among other hallmarks, cancer is a result of defects in maintaining the cellular transcriptional memory, leading to lack of differentiation, or anaplasia. Hence, dysregulation of the transcriptional maintenance system can lead to malignancy.

[00112] The Polycomb Group (PcG) and trithorax Group (trxG) have been implicated in maintenance of the cellular memory and prevent changes in cell type specific transcription programs. They are known to be involved in the process of histone modification, DNA methylation and chromatin transformation. To establish and maintain the cell identity, many pathways are involved in repressing specific sets of genes. From *Drosophila* to mammals, the genes of Polycomb group and trithorax group are widely conserved and they maintain the transcription patterns which are set in the first stages of embryonic life, and in the adulthood. TrxG and PcG respectively regulate active and repressed genes related to development and cell cycle regulation. Multiple lines of evidence show that PcG proteins are dysregulated and play important roles in cancer progression.

[00113] Among various epigenetic modifying enzymes, the Polycomb repressor complex 2 (PRC2) is of particular importance since its key component EZH2, a histone methyltransferase specific for repressive H3K27 trimethylation (H3K27me3), is often deregulated in human cancers. The role of EZH2-mediated gene silencing has been implicated in regulating cancer cell proliferation, invasion and metastasis. Moreover,

increasing number of EZH2 or H3K27me3 target genes linked to important cancer pathways have been recently identified. EZH2 is overexpressed in hormone-refractory, metastatic prostate cancer, and is a biomarker of prostate metastases. Hence, EZH2 and its associated histone methyltransferase activity in the majority of cancers, which suggest that EZH2 enzymatic activity is a promising cancer drug target.

[00114] EZH2 inhibitors such as for example, S-adenosylhomocysteine hydrolase (SAHH) inhibitor 3-deazaneplanocin A (DZNep) that can modulate histone methylation and disrupt EZH2 complex, have been shown to induce apoptosis in some cancer cell lines. However, DZNep has numerous side effects and produces widely varied response in a cancer-specific manner. The term "inhibitor" or "antagonist" is used in the broadest sense herein, and is understood to include all molecules that partially or entirely block, inhibit, and/or neutralize at least one biological activity of their target (e.g., EZH2). For example, the term "antagonist antibody" refers to an antibody that inhibits or decreases the biological activity of an antigen, for example EZH2, that the antibody binds. In some examples, the antibody or the antigen binding fragment thereof specifically binds to EZH2 to reactivate expression of genes repressed by EZH2 of genes, thereby, for example, inhibiting proliferation of the target tumor cell.

[00115] It is thus an object of the invention to develop combinatorial pharmacologic approaches for epigenetic gene reactivation. Without being bound by any theories, the present inventors surprisingly found that IFNGR1, the gene that encodes for interferon-gamma receptor gamma subunit has frequently been observed to be down-regulated in as significant number of prostate cancer cell lines and advanced prostate cancer tumours. As indicated above, IFN- γ , the naturally occurring ligand of IFNGR1, has been previously used as an anti-tumour agent to treat cancers including prostate cancer but with limited success.

[00116] In the present disclosure, it is shown that down-regulation of the IFNGR1 receptor leads to desensitization of cancer cells to an enhancer of interferon-gamma receptor activity treatment, such as IFN- γ treatment. Since the IFN- γ pathway can only be specifically be activated the IFN- γ ligand, the non-responsiveness to IFN- γ treatment due to the absence or low number of IFNGR1 allows the prostate cancer cells to evade cell death by reduced activation of the IFN- γ -STAT1 tumour suppressor pathway.

[00117] Advantageously, the inventors further identified EZH2 to be an epigenetic factor that mediates the repression of genes including but not limited to IFNGR1 (encoding for IFN-

γ Receptor subunit 1), IFNAR2, IFI16, IFNAR1, IFNGR2, IFIT1, GBP1, IRF9, STAT2, IFIH1, STAT1, MX1, IFIT2, IFI16, IFI44, IFIT3 and ISG15 in highly metastatic prostate cancer cells. Other exemplary representative genes are shown in Table 2 below. Additionally, the inventors found that in addition to prostate cancer, IFNGR1 level is also downregulated in
5 cancers including but not limited to liver, lung, breast, leukemia such as ALL ovarian, and cancers when compared to IFNGR1 level in normal (non-tumour or non-cancerous cells, tissues, organs or organisms).

[00118] Accordingly, in one example there is provided a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2)
10 inhibitor and an enhancer of interferon-gamma receptor activity. In another example, disclosed herein is the pharmaceutical composition described herein, wherein the interferon-gamma receptor can be the interferon-gamma receptor 1 (IFNGR1) encoding for interferon-gamma receptor (IFNGR1) subunit 1. In a further example, the interferon gamma receptor can be the interferon-gamma receptor 2 (IFNGR2) encoding for interferon-gamma receptor (IFNGR1) subunit 2. In one example, disclosed is the pharmaceutical composition described
15 herein, further comprising one or more pharmaceutically acceptable excipients, vehicles or carriers. As used herein, the term "enhancer" is used in its broadest sense and is understood to include all molecules that partially or entirely activate, improve, and/or enhance at least one biological activity of their target (e.g., interferon-gamma receptor). The enhancer can act
20 directly (e.g. by binding to the receptor) or indirectly (e.g. by inhibiting molecules that interfere with the activity of the interferon-receptor, such as IFNGR1, or by improving the binding of a ligand to the receptor).

[00119] As used herein, the term "pharmaceutical composition" refers to the presence of at least one histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor
25 and at least one an enhancer of interferon-gamma receptor activity as defined herein. Thus, a pharmaceutical composition of the invention may comprise two or more histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitors comprising but not limited to a small molecule inhibitor of EZH2, such as the inhibitors described in Table 1, a EZH2 binding protein, such as an antibody, and a nucleic acid molecule or conjugate thereof
30 capable of inhibiting the expression of EZH2, such as a siRNA, a miRNA or an aptamer and two or more enhancer of interferon-gamma receptor activity comprising but not limited to a small molecule enhancer, IFN- γ , a IFNGR1-binding molecule, such as a peptide, a protein or

a nucleic acid. For example, the pharmaceutical composition as disclosed herein may comprise a combination of DZNep and a siRNA capable of binding and inhibiting translation of EZH2 mRNA and a combination of IFN- γ and a molecule capable of neutralizing and inhibiting binders of IFN- γ . By binder of IFN- γ , it is meant any molecule capable of binding
5 IFN- γ that may inhibit its ability to bind to its receptor IFNGR1. Such molecules may include proteins such as enzymes (e.g. proteases), antibodies, or peptides. The pharmaceutical composition may further optionally comprise at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.

[00120] As used herein, the term "pharmaceutically acceptable carrier", "pharmaceutically
10 acceptable vehicle" or "pharmaceutically acceptable excipient" is intended to mean, without limitation, any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, emulsifier, or encapsulating agent, such as a liposome, cyclodextrins, encapsulating polymeric delivery systems or polyethyleneglycol matrix, which
15 is acceptable for use in subjects, preferably humans. It preferably refers to a compound or composition that is approved or approvable by a regulatory agency of the Federal or State government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals and more particularly in humans. The pharmaceutically acceptable vehicle can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for
20 example, glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. Additional examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as,
25 but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate. Prevention of the action of microorganisms can be achieved by addition of antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many
30 cases, isotonic agents are included, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of injectable

compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.

[00121] A compound or compounds as described herein, as well as their pharmaceutically useable salts, together with one or more conventional excipients, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use. A typical preparation will contain from about 5% to about 95% active compound or compounds (w/w).

[00122] The term "preparation" or "dosage form" is intended to include both solid and liquid formulations of the active compound and one skilled in the art will appreciate that an active ingredient can exist in different preparations depending on the target organ or tissue and on the desired dose and pharmacokinetic parameters.

[00123] The term "excipient" as used herein refers to a compound that is useful in preparing a pharmaceutical composition, generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. The compounds of this invention can be administered alone but will generally be administered in admixture with one or more suitable pharmaceutical excipients, diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.

[00124] "Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.

[00125] A "pharmaceutically acceptable salt" form of an active ingredient may also initially confer a desirable pharmacokinetic property on the active ingredient which were absent in the non-salt form, and may even positively affect the pharmacodynamics of the

active ingredient with respect to its therapeutic activity in the body. The phrase “pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-
10 disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid,
15 muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

[00126] Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier may be one or more substances which
20 may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the
25 necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers,
30 buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

[00127] Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in
5 aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose,
10 sodium carboxymethylcellulose, and other well-known suspending agents.

[00128] Advantageously, the present disclosure shows that IFNGR expression (e.g. IFNGR1 expression) can be restored in diseased cells where expression of IFNGR is absent or downregulated because of EZH2 overexpression. The inventors surprisingly found that EZH2 overexpression results in repression of IFNGR expression. Hence, the subsequent
15 absence or low numbers of IFNGR receptors at the surface of the diseased cells, such as for example, cancer cells may lead to unresponsiveness of cells to IFN- γ stimulation. In turn, the IFN- γ -STAT1 tumour suppressor pathway may not be activated by IFN- γ .

[00129] Thus, the present disclosure relates to the restoration of IFNGR expression through reactivation (or derepression) of interferon-gamma receptor gene, by inhibition of EZH2
20 enzyme. In one example, the present invention discloses a pharmaceutical composition that may comprise at least one EZH2 inhibitor, thereby for example restoring the EZH2-mediated repression of IFNGR expression such as IFNGR1 and at least one enhancer of interferon gamma activity, to reactivate the receptors that Examples of EZH2 inhibitors are presented below and may include but are not limited to small chemical molecules (or agents or drugs)
25 inhibitors that inhibit the activity of EZH2, molecules that inhibit the expression of EZH2, such as siRNA, miRNA or aptamers, or antibodies that bind EZH2, thereby inhibiting the EZH2-mediated repression of IFNGR, such as IFNGR1 in affected cells. Advantageously, the restoration of IFNGR1 through EZH2 may not require amount or dosage of EZH2 inhibitor that would lead to potential detrimental side effects to the patient. The present technology
30 proposes treatment and diagnosis of advanced prostate cancer and other cancers comprising the use of EZH2 inhibitors in combination with IFN- γ .

[00130] In one example, there is provided an inhibitor of EZH2 including but not limited to the small molecules inhibitors presented in Table 1 below.

Table 1. Small molecules EZH2 inhibitors

EZH2 Inhibitors
(-)-1-[(1R,4R,5S)-3-(Hydroxymethyl)-4,5-dihydroxy-2-cyclopenten-1-yl]4-aminoimidazo[4,5-c]pyridine hydrochloride (DZNep; 3-deazaneplanocin A)
1-{[4-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-2-yl]sulfanyl}-3,3-dimethylbutan-2-one
4-[4-(4-methyl-1,3-thiazol-2-yl)phenyl]-1,2,3-thiadiazole
2-[(3,4-dichlorophenyl)carbamoyl]amino}benzoic acid
N-(2-methylquinolin-6-yl)quinoxaline-2-carboxamide
2-[(4-tert-butylphenyl)carbonyl]-1H-imidazole
1-(2-hydroxyphenyl)-3-[4-(methoxymethoxy)phenyl]propane-1,3-dione
N-(3-acetylphenyl)-8-methoxy-2-oxo-2H-chromene-3-carboxamide
1-{3-[4-(2-phenylethynyl)phenyl]-1H-pyrazol-1-yl}ethan-1-one
3-(thiophen-2-yl)benzoic acid
5-(6-methoxynaphthalen-2-yl)-1H-pyrazole
4-methyl-5-[3-(methylsulfanyl)-1H-pyrazol-5-yl]-2-(thiophen-2-yl)-1,3-thiazole
2-[[2-(2-chloro-6-fluorophenyl)methyl]sulfanyl]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethan-1-one
3-(3-chlorophenyl)-5-(thiophen-3-yl)-1,2,4-oxadiazole
2,3-dihydro-1-benzofuran-5-ylmethanimidamido thiophene-2-carboxylate
N-(2,3-dihydro-1,4-benzodioxin-6-yl)[(furan-2-ylmethyl)carbamothioyl]formamide
N-[4-(diethylamino)phenyl]-3-methylbenzamide
3-[5-(1,2-oxazol-3-yl)thiophen-2-yl]-5-phenyl-1,2,4-oxadiazole
ethyl(2E)-2-cyano-3-[(E)-{[4-dimethylamino]phenyl}methylidene]amino}(methane)sulfonimidamido}prop-2-enoate
(2Z)-2-(4-ethylphenyl)-3-(4-methoxyphenyl)prop-2-enenitrile
5-tert-butyl-3-methyl-N-phenylthieno[3,2-b]thiophene-2-carboxamide
5-(1-butyl-2-oxo-2,3-dihydro-1H-indol-3-ylidene)-2-(piperidin-1-yl)-4,5-dihydro-1,3-thiazol-4-one
(2E,6E)-2,6-bis(thiophen-2-ylmethylidene)cyclohexan-1-one
2-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-benzothiazole
2-chloro-N-[3-hydroxy-4-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-5-nitrobenzamide
6-chloro-2-phenyl-4H-thiochromen-4-one methyl 2-(3,4-dihydro-2H-1,5-benzodioxepine-7-amido)benzoate
3-chloro-N,N-dimethyl-4-[(1E)-[2-(quinoxalin-2-yl)hydrazin-1-ylidene]methyl]aniline
(2E)-1-(2-methyl-1H-indol-3-yl)-3-(thiophen-2-yl)prop-2-en-1-one
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(thiophen-2-yl)-1,3-thiazole-4-carboxamide
4-[(E)-2-(1-methyl-1H-1,3-benzodiazol-2-yl)ethenyl]-1,3-thiazole
3-(4-bromophenyl)-3,4-dihydro-1,2,3-benzotriazin-4-one
N-(2,4-dichlorophenyl)-3,4-dihydro-2H-1-benzopyran-2-carboxamide
N,N-dimethyl-4-[(E)-2-phenylethenyl]aniline
2-(3,4-dichlorophenyl)quinoxaline
N-(3-tert-butyl-1H-pyrazol-5-yl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide
(2E)-2-(1,3-benzothiazol-2-yl)-3-(4-chlorophenyl)prop-2-enenitrile
(4-tert-butylphenyl)methanimidamido 2-(thiophen-2-yl)acetate
5-[4-(3-methyl-1-benzothiophen-2-yl)-1,3-thiazol-2-yl]-1,2-oxazole
1-(4-fluorophenyl)-3-(1-phenyl-5-propyl-1H-pyrazol-4-yl)urea
2-[(2Z)-2-phenyl-2-[(2E)-2-(thiophen-2-ylmethylidene)hydrazin-1-ylidene]ethyl]-1H-1,3-benzodiazole
N-{7-oxo-8-oxa-4-thiatricyclo[7.4.0.0 [^] {2,6}]trideca-1(9),2,5,10,12-pentaen-5-yl}thiophene-2-

carboxamide

2-(2-chlorophenyl)-1-[4-(dimethylamino)phenyl]ethan-1-one ethyl 4-cyano-1-(4-methylphenyl)-1H-pyrazole-3-carboxylate
 3-hydrazinylquinoxaline-2-thiol
 1-[(5-tert-butylthiophen-2-yl)carbonyl]piperidine
 3-[5-(2-phenylethynyl)thiophen-2-yl]-1-(thiophen-2-ylcarbonyl)-1H-pyrazole
 2,5-dichloro-N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)thiophene-3-carboxamide
 1-tert-butyl-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazole-3-carboxamide
 4-(5-propylpyridin-2-yl)benzotrile
 5-(4-chlorophenyl)-3-(2,2-dichloroacetamido)thiophene-2-carboxamide
 (4-methanesulfonamidophenyl)methanimidamido thiophene-2-carboxylate
 ethyl 7-methyl-2-phenylpyrazolo[1,5-a]pyrimidine-6-carboxylate
 6-(4-chlorophenyl)-3-phenylthieno[2,3-e][1,2,4]triazine
 1-{1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl}-2,3-dihydro-1H-indole
 5-(4-chlorophenyl)-2-(4-methylphenyl)-2H-1,2,3,4-tetrazole
 4-[(1 E)-[2-(3,5-dichloropyridin-4-yl)hydrazin-1-ylidene]methyl]-N,N-dimethylaniline
 3-(5-tert-butyl-1,2-oxazol-3-yl)-1-phenylurea
 (4-chlorophenyl)methanimidamido 3-chlorothiophene-2-carboxylate
 N-{4-[(E)-2-phenyldiazen-1-yl]phenyl}acetamide
 methyl 4-[(pyrimidin-2-ylsulfanyl)methyl]benzoate
 2-phenylimidazo[1,2-a]pyridine
 6-chloro-2-phenyl-4H-thiochromen-4-one
 2-[[4-(4-methylphenyl)methyl]sulfanyl]-5-(pyrazin-2-yl)-1,3,4-thiadiazole
 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
 (E)-[I-(1H-pyrrol-2-yl)ethylidene]amino N-(4-chlorophenyl)carbamate
 1-benzoyl-3,2,3-dihydro-1H-inden-5-ylthiourea
 1-{1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl}-2,3-dihydro-1H-indole
 N,5-diphenyl-1,3,4-oxadiazole-2-carboxamide
 (3Z)-3-(2,3-dihydro-1-benzofuran-5-ylmethylidene)-2,3-dihydro-1H-indol-2-one
 [(3-methylbutyl)sulfanyl]-N-phenylformamide
 2,4-dihydroxy-5,7-diphenylpyrano[2,3-d]pyrimidin-8-ium perchlorate
 ethyl 7-hydroxy-9-oxo-9H-xanthene-2-carboxylate
 [(3,5-Dimethyl-1-(2-methyl-2-propanyl)-1H-pyrazol-4-yl)methylene]aminooxy}{[3-(trifluoromethyl)phenyl]amino}methanone
 5-[(4-iodophenyl)amino]-3-phenyl-1,3-thiazolidine-2,4-dione
 N-(furan-2-ylmethyl)-2-[methane(4-phenoxyphenyl)sulfonamido]acetamide
 N-(3-methoxyphenyl)-6-phenylpyridazin-3-amine
 ethyl (2E)-3-[(2-chlorophenyl)amino]-2-cyanoprop-2-enoate
 1-[3-chloro-1-benzothiophen-2-yl]carbonyl]-1H,2H,3H,4H,6H,10bH-pyrimido[2,1-a]isoindol-6-one
 2-(4-chlorophenyl)-5-[(cyclopropylmethyl)sulfanyl]-1,3,4-oxadiazole
 1-[6-(benzyloxy)-3-tert-butyl-2-hydroxyphenyl]ethan-1-one
 3-[(1 E)-1-[(2,2-dichloroethenyl)imino]-2,2-dimethylpropyl]-1-(4-methylphenyl)thiourea
 6,7-dimethyl-2-phenylquinoxaline
 5-(2,3-dihydro-1-benzofuran-5-yl)-3-(4-fluorophenyl)-1,2,4-oxadiazole
 2-{4-[(4-methylphenyl)methoxy]phenyl}acetonitrile
 1-cyclohexyl-3-8-oxatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-5-ylurea
 5-(1,2,3-thiadiazol-4-yl)-3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
 N-(2-methylquinolin-6-yl)-2-phenylacetamide
 3-(piperidin-1-ylcarbonyl)-5-(thiophen-2-yl)-1,2-oxazole
 N-(3,4-dimethylphenyl)[(E)-N'-(thiophen-2-ylmethylidene)hydrazinecarbonyl]formamide
 2-(2,3-dimethoxyphenyl)-2,3-dihydro-1,3-benzothiazole
 2-methyl-5-(naphthalen-2-yl)-1,3-thiazole hydrobromide

(cyclohexylcarbamothioyl)-N-(4-fluorophenyl)formamide
4-(1,3-benzothiazol-2-yl)-1-methyl-1H-pyrazol-3-amine
(4-tert-butylphenyl)methanimidamido 5-methyl-1,2-oxazole-3-carboxylate
N-[2-(methylsulfanyl)-1,3-benzothiazol-6-yl]thiophene-2-carboxamide
N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2H-1,3-benzodioxole-5-carboxamide
(2E)-3-(2-chlorophenyl)-N-(2-methylbut-3-yn-2-yl)prop-2-enamide
1-naphthalen-1-yl-3-8-oxatricyclo[7.4.0.0^{2,7}]trideca-1(13),2,4,6,9,11-hexaen-5-ylthiourea
3-methyl-N-phenyl-1-benzothiophene-2-carbothioamide
5-(2,5-dichlorophenyl)-N-[2-(trifluoromethyl)phenyl]furan-2-carboxamide
3-(5-methyl-1,2-oxazol-3-yl)-5-(thiophen-2-yl)-1,2,4-oxadiazole
N-(1H-indazol-3-yl)-3-methoxybenzamide
2-(4-tert-butylphenyl)-5-[(propane-1-sulfonyl)methyl]-1,3,4-oxadiazole
1-[2-(4-chlorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]ethan-1-one
(4-methanesulfonamidophenyl)methanimidamido N-(4-methylphenyl)carbamate
N-phenyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine hydrochloride
7-nitro-N-(2-phenylethyl)-1H-indole-2-carboxamide
2-{{(2E)-4-(pyridin-2-ylsulfanyl)but-2-en-1-yl}sulfanyl}pyridine
4-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-2-[(3-nitropyridin-2-yl)sulfanyl]pyrimidine
4-(4-chlorophenyl)-2-[(4-methoxyphenyl)methyl]-1,3-thiazole
(3Z)-3-[[5-(thiophen-2-yl)thiophen-2-yl]methylidene]-2,3-dihydro-1H-indol-2-one
N-(4-bromo-2,5-difluorophenyl)-2,3-dimethylbenzamide
sodium N-phenyl(phenylamino)carboximidate
2-(benzylsulfanyl)-N-(2,3-dihydro-1H-inden-2-yl)acetamide
(5Z)-5-[[5-methylfuran-2-yl]methylidene]-3-phenyl-1,3-thiazolidine-2,4-dione
N-{4-[(3-chlorophenyl)carbamoyl]phenyl}thiophene-2-carboxamide
N-[(3-chlorophenyl)methyl]-5-(methylsulfanyl)-1,3,4-thiadiazol-2-amine
(E)-2-(phenylamino)-3-(phenylimino)guanidine
(2Z)-3-methyl-2-[2-(3-methyl-2,3-dihydro-1,3-benzoxazol-2-ylidene)hydrazin-1-ylidene]-2,3-dihydro-1,3-benzoxazole
3-[2-(2H-1,4-benzothiazin-3-yl)hydrazin-1-yl]-2H-1,4-benzothiazine
3-(3,4-dimethyl-1,2-oxazol-5-yl)-1-[4-(dimethylamino)-3,5-difluorophenyl]carbonylurea
(3Z)-3-[2-(2,5-difluorophenyl)hydrazin-1-ylidene]piperidin-2-one
N'-[(E)-[1-(1-benzofuran-2-yl)ethylidene]amino](methylsulfanyl)methanimidamide
(2Z)-3-(9H-fluoren-2-ylcarbamoyl)prop-2-enoic acid
4-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)diazen-1-yl]-N,N-diethylaniline
4,5-dichloro-N-(3-chloro-4-fluorophenyl)-1,2-thiazole-3-carboxamide
5-[4-(4-methoxyphenoxy)phenyl]-1H-pyrazole
1-cyclohexyl-3-[(Z)-(1H-pyrazol-3-ylmethylidene)amino]thiourea
[5-(4-chlorophenyl)-3-methyl-2-sulfanylidene-1,3,4-thiadiazinan-6-ylidene]amino 5-tert-butylthiophene-2-carboxylate
N-(2-phenylethyl)benzenecarbothioamide
5-amino-3-methyl-2-N-phenylthiophene-2,4-dicarboxamide
3-amino-5-(thiophen-3-yl)thiophene-2-carboxamide
(2E)-2-[[4-(trifluoromethoxy)phenyl]imino]-3,4-dihydro-2H-1,3-benzoxazin-4-one
3-hydroxy-9H-xanthen-9-one
4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol
(3-chlorophenyl)methanimidamido 6-(2,2,2-trifluoroethoxy)pyridine-3-carboxylate
5-phenyl-3-(pyrrolidin-1-yl)-1,2-thiazole-4-carbonitrile
7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
2-(4-fluorophenyl)-2H,3H,5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrimidin-3-one
(4-chlorophenyl)methanimidamido 2,6-difluorobenzoate
2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one

6,7-dimethoxy-2-phenylquinoxaline
 6-methoxy-3-phenyl-[1,2,4]triazolo[4,3-a]pyridazine
 5-[4-(furan-2-ylcarbonyl)piperazin-1-yl]-3-(thiophen-2-yl)-1,2,4-thiadiazole
 (E)-{1-[2-(4-chlorophenoxymethyl)-1,3-thiazol-4-yl]ethylidene} amino benzoate
 N-[(2-chloro-6-fluorophenyl)carbonyl]-N'-(4-methylpyridin-2-yl)ethanediamide
 (E)-hydroxy[1-(2-phenyl-1,3-thiazol-4-yl)ethylidene]amine
 ethyl 1-{{4-(trifluoromethoxy)phenyl}carbonyl}piperidine-4-carboxylate
 3-(3-methyl-1H-indol-1-yl)-N-[4-(morpholin-4-yl)phenyl]propanamide
 6,8-dimethyl-1-methylidene-2-(4-methylphenyl)-1,4-dihydronaphthalene
 N'-(2-methyl-1,3-thiazol-4-yl)methoxy-4-(trifluoromethyl)benzene-1-carboximidamide
 1-[4-(benzyloxy)phenyl]-3-[(3-cyanopyridin-2-yl)amino]urea
 2-phenylimidazo[1,2-a]pyridine
 3-(morpholin-4-yl)-5-[4-(trifluoromethyl)phenyl]-1,2-thiazole-4-carbonitrile
 N-(2-chlorophenyl)-2-[(3-cyano-6-acetylpyridin-2-yl)sulfanyl]acetamide
 3-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-5-methyl-1,2-oxazole
 N-(3-bromo-5-methylpyridin-2-yl)-4-ethylbenzamide
 2-(5-methyl-1,2-oxazol-3-yl)-5-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazole
 (E)-[1-(3-methyl-1-benzothiophen-2-yl)ethylidene]amino N-phenylcarbamate
 N-(2,3-dihydro-1H-inden-2-yl)-3-(3-methyl-1H-indol-1-yl)propanamide
 1,3-dimethanesulfonyl-2,3-dihydro-1H-1,3-benzodiazole
 methyl 2-[5-methyl-2-(thiophene-2-amido)-1,3-thiazol-4-yl]acetate
 4-[(5-{{(4-chlorophenyl)sulfanyl}methyl} furan-2-yl)carbonyl]morpholine
 2-oxo-2-phenylethyl 2,3-dimethoxybenzoate
 N-(4-chlorophenyl)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide
 (2,4-dichlorophenyl)methyl N-[(2-fluorophenyl)carbonyl]carbamate
 2-[(4-chlorophenyl)carbonyl]-1-benzofuran
 4-chlorophenyl 2,3-dihydro-1-benzofuran-5-carboxylate
 2-[4-(dimethylamino)phenyl]-1,2,3,4-tetrahydroquinolin-4-one
 [6-(ethylsulfanyl)pyridin-3-yl]methanimidamido thiophene-2-carboxylate
 N-[(6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl]-6-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-1-(propan-2-yl)-1H-indazole-4-carboxamide (GSK343)
 N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-((1S)-1-methylpropyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide (GSK126)
 N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indazole-4-carboxamide (GSK926)

[00131] In one specific non-limiting example, there is provided the pharmaceutical composition as described herein wherein said inhibitor is (-)-1-[(1R,4R,5S)-3-(Hydroxymethyl)-4,5-dihydroxy-2-cyclopenten-1-yl]4-aminoimidazo[4,5-c]pyridine

5 hydrochloride (DZNep; 3-deazaneplanocin A).

[00132] In one example, the disclosure relates to a pharmaceutical composition as described herein, comprising at least one EZH2 inhibitor and at least one enhancer of IFN- γ receptor activity, wherein said inhibitor is an EZH2-binding protein. As used herein the term "protein", "peptide" or "polypeptide" comprises a polymer of amino acid residues linked
 10 together by peptide (amide) bonds. The term(s), as used herein, refers to proteins, polypeptides, and peptide of any size, structure, or function. Typically, a peptide or

polypeptide will be at least three amino acids long. A peptide or polypeptide may refer to an individual protein or a collection of proteins. Inventive proteins preferably contain only natural amino acids, although non-natural amino acids that is, compounds that do not occur in nature but that can be incorporated into a polypeptide chain and/or amino acid analogs as are known in the art may alternatively be employed. Also, one or more of the amino acids in a peptide or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. A peptide or polypeptide may also be a single molecule or may be a multi-molecular complex, such as a protein. A peptide or polypeptide may be just a fragment of a naturally occurring protein or peptide. A peptide or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof. As used herein "dipeptide" refers to two covalently linked amino acids.

[00133] Thus, the term "EZH2-binding protein" as used herein refers to peptides, polypeptides or proteins having the ability to specifically bind to the EZH2 protein. For example, the EZH-binding protein may be an antibody or an antigen binding fragment. The term "antigen binding fragment(s)" used herein refers to fragments comprising portions of an intact antibody including some or all of the antigen binding regions and having the ability to bind specifically to the antigen of the intact antibody. For example, the antigen binding fragment may be a Fab fragment, a Fab' fragment, aF(ab')₂ fragment, a Fv fragment, or a scFv fragment, but is not limited thereto. A Fab fragment contains the variable region and the constant region of a light chain and a variable region and the first constant domain (CH1) of a heavy chain. A Fab fragment possesses one antigen binding site. A Fab' fragment is different from a Fab fragment in that Fab' additionally has the hinge region with at least one cysteine residue at the C-terminal end of CH1. A F(ab')₂ fragment comprises a pair of Fab fragments, which are generally covalently linked together by a disulfide bond between hinge cysteine residues near their carboxy termini. A Fv fragment is an antibody fragment which contains a complete antigen recognition and binding site, consisting of a dimer of one heavy and one light chain variable domain in tight association. Recombinant techniques for producing the Fv fragment are well-known in the art. A Fv fragment may have a structure in which the heavy chain and the light chain variable regions are linked by a non-covalent bond. Single-chain Fv (scFv) fragments generally may have a dimer structure in which the heavy chain and

the light chain variable regions are covalently bound via a peptide linker whereas disulfide-linked (scFv)₂ fragments may have a structure in which two scFv fragments are directly linked to each other at the C-termini through a disulfide bond. The antigen binding fragment may be obtained using a protease to digest an intact antibody, such as papain to obtain Fab fragments or pepsin to obtain F(ab')₂ fragments. Alternatively, the antigen binding fragment may be prepared by a genetic recombinant technique.

[00134] In one non-limiting, the disclosure relates to a pharmaceutical composition as described herein, wherein said EZH2-binding protein is an antibody or fragment thereof. The term "antibody" used herein includes intact antibodies as well as antigen binding fragments of intact antibody molecules, i.e., fragments having antibody-like specific binding to an antigen, for example, the EZH2 protein.

[00135] The antibody may be a monoclonal antibody, a bispecific antibody, a non-human antibody, a humanized antibody, a human antibody, a chimeric antibody, a Fab fragment, a F(ab') fragment, a scFv fragment, a disulfide-bond Fv (sdFv) fragment, an anti-idiotypic (anti-Id) antibody, and an epitope-binding fragment of these antibodies, but is not limited thereto.

[00136] The antibody may be a humanized antibody or a human antibody. A humanized form of a non-human antibody, such as a murine antibody, may be a chimeric antibody which contains minimal sequence derived from the non-human immunoglobulin, chains of the immunoglobulin, or fragments thereof, such as Fab, Fab', F(ab')₂, and Fv.

[00137] A non-human antibody is humanized using a method known in the art. In general, a humanized antibody has at least one amino acid residue introduced from a non-human donor. The humanization of a non-human antibody may be performed by replacing residues from a CDR of a human antibody with CDR residues from the antibody of the non-human species, such as mouse, rat, rabbit, or non-human primate, having the desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.

[00138] A human antibody possesses an amino acid sequence which corresponds to that of an antibody produced by a human and/or has been made using any of the techniques for making human antibodies. Human antibodies may be produced using various techniques known in the art, such as phage display, genetic recombinant techniques, and/or cell engineering.

[00139] Effector regions of human antibodies may interact with complement and effector cells of the human immune system. In addition, the human immune system does not recognize human antibodies as foreign materials, and thus, the immune reaction against human antibodies introduced into a human may be significantly less severe than that against non-human and chimeric antibodies introduced into a human. Moreover, human antibodies have a long half-life in the blood stream, and therefore, dosage and frequency of administration may be reduced.

[00140] The term "chimeric antibody" used herein refers to an antibody with sequences derived from two different species.

[00141] In another example, disclosed herein is a pharmaceutical composition as disclosed herein, wherein said inhibitor is a nucleic acid molecule or conjugate thereof. The EZH2-binding protein a EZH2The role of inhibiting EZH2 in our study is to sensitize the advanced prostate cancer cells to IFN- γ induced cell death. This effect is achieved by restoring the expression of IFNGR1 by relieving the repression mediated by EZH2 through the usage of another EZH2 inhibitor, DZNep. The "nucleic acid molecule" or "polynucleotide" refers to polymers of nucleotides, and includes but is not limited to DNA, RNA, DNA/RNA hybrids including polynucleotide chains of regularly and/or irregularly alternating deoxyribosyl moieties and ribosyl moieties (i.e., wherein alternate nucleotide units have an —OH, then and then an —OH, then an —H, and so on at the 2' position of a sugar moiety), and modifications of these kinds of polynucleotides, wherein the attachment of various entities or moieties to the nucleotide units at any position are included. Thus as used herein, a "nucleic acid molecule EZH2 inhibitor" may be any nucleic acid or/and polynucleotide as defined herein comprising but not limited to a nucleotide, an oligonucleotide, a polynucleotide such as for example, a DNA single or double stranded, an RNA, an aptamer, a microRNA (miRNA), a locked nucleic acid, a small interfering RNA (siRNA) or a peptide nucleic acid (PNA) that has the ability to inhibit the expression of the EZH2 gene, or EZH2 protein, or the catalytic or functional activity of EZH2 responsible for repressing the activity of molecules, such as for example, INFGR receptor. In other words, the nucleic acid has the ability to inhibit the repressive activity of EZH2 as defined herein.

[00142] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or "conjugates" which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the

invention can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention can include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugates groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenan-thridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion.

[00143] Particular oligonucleotides and oligonucleotide analogs can include linear sequences up to about 200 nucleotides in length, for example a sequence (such as DNA or RNA) that is at least 6 bases, for example at least 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100 or even 200 bases long, or from about 6 to about 50 bases, for example about 10-25 bases, such as 12, 15 or 20 bases.

[00144] Oligonucleotides composed of 2'-deoxyribonucleotides (oligodeoxyribonucleotides) are fragments of DNA and are often used in the polymerase chain reaction, a procedure that can greatly amplify almost any small amount of DNA. There, the oligonucleotide is referred to as a primer, allowing DNA polymerase to extend the oligonucleotide and replicate the complementary strand.

[00145] In one specific non-limiting example, the nucleic acid molecule as described herein is a small interfering RNA. As used herein, the term "siRNA" is meant to refer to a small inhibitory RNA duplex that induces gene silencing by operating within the RNA interference ("RNAi") pathway. These molecules can vary in length (generally 18-30 base pairs) and contain varying degrees of complementarity to their target mRNA in the antisense strand. Some, but not all, siRNA have unpaired overhanging bases on the 5' or 3' end of the sense strand and/or the antisense strand. The term "siRNA" includes duplexes of two separate strands, as well as single strands that can form hairpin structures comprising a duplex region.

[00146] Each siRNA can include between 17 and 31 base pairs, more preferably between 18 and 26 base pairs, and most preferably 19 and 21 base pairs. Some, but not all, siRNA

have unpaired overhanging nucleotides on the 5' and/or 3' end of the sense strand and/or the antisense strand. Additionally, the term "siRNA" includes duplexes of two separate strands, as well as single strands that can form hairpin structures comprising a duplex region, which may be referred to as short hairpin RNA ("shRNA").

5 [00147] As used herein, the terms "shRNA" or "hairpins" are meant to refer to unimolecular siRNA comprised by a sense region coupled to an antisense region through a linker region. A shRNA may have a loop as long as, for example, 4 to 30 or more nucleotides. In some embodiments it may be preferable not to include any non-nucleotides moieties. The shRNA may also comprise RNAs with stem-loop structures that contain
10 mismatches and/or bulges, micro-RNAs, and short temporal RNAs. RNAs that comprise any of the above structures can include structures where the loops comprise nucleotides, non-nucleotides, or combinations of nucleotides and non-nucleotides. The sense strand and antisense strand of a shRNA are part of one longer molecule or, in the case of fractured hairpins, two (or more) molecules that form a fractured hairpin structure.

15 [00148] In one example, there is provided a pharmaceutical composition as described herein, wherein said enhancer is interferon-gamma (IFN- γ). It has been shown herein that EZH2 inhibitors sensitize cells to IFN- γ receptor enhancer, such as for example, IFN- γ . Accordingly, in response to derepression of the IFNGR1 gene, the IFNGR1 receptor is expressed at the surface of the target cells. Consequently, IFNGR1 ligands, such as for
20 example, IFN- γ may bind to the receptor and activate the STAT1 tumour suppressor pathway. For example, Fig. 1 shows that the epigenetic repression of IFNGR1 is mediated by EZH2 and is reversible. The inventors demonstrated that, for example DZNep is a potent inhibitor of EZH2 that effectively relieve the repression of IFNGR1 and allows activation of the IFN- γ -STAT1 pathway in cancer cells, such as prostate cancer cells. In other words,
25 DZNep sensitize the cells to IFN- γ . The specificity of DZNep towards EZH2 is further shown in Fig.2. Thus, adding IFN- γ to EZH2 inhibitor treatment surprisingly enhances the beneficial therapeutic effect of EZH2 inhibitor.

[00149] In one example, disclosed herein is a pharmaceutical composition as described herein, wherein said inhibitor is DZNep and said enhancer is IFN- γ . In other non-limiting
30 examples, the pharmaceutical composition may comprise IFN- γ and an inhibitor of EZH2, as described herein, including but not limited to a small molecule inhibitor, a EZH2-binding

protein such as an EZH2 antibody and a nucleic acid such as at least one siRNA capable of silencing EZH2 expression.

[00150] The pharmaceutical compositions described herein, comprising at least one EZH2 inhibitor and at least one IFNGR enhancer can be useful for treating one or more diseases responsive to relief from EZH2 repression and the IFN- γ pathway activation. Without wishing to be bound to any particular theory, it is believed that the interaction of the compounds disclosed herein with EZH2 results in the inhibition of EZH2 activity and thus in the pharmaceutical utility of these compounds. Thus in one example, there is provided a pharmaceutical composition as described herein, for use in therapy. Accordingly, the disclosure includes a method of treating a mammal, for instance a human, having a disease responsive to inhibition of EZH2 activity and activation of IFNGR1, comprising administering to the mammal having such a disease, an effective amount of at least one pharmaceutical composition provided herein. In one non-limiting specific example, there is provided a method of treating a patient having cancer comprising administration of the pharmaceutical composition as defined herein. In another example, the method as disclosed herein, comprises administration of the pharmaceutical composition comprising DZNep as a EZH2 inhibitor and IFN- γ as an enhancer of interferon gamma receptor activity to the patient in need thereof. An effective concentration may be ascertained experimentally, for example by assaying blood concentration of the compound, or theoretically, by calculating bioavailability.

[00151] The term "treatment" (and grammatical variants thereof) as used herein is intended to be construed broadly and includes a reference to any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever. Accordingly, the term "treatment" can include any of the following (i) the prevention or inhibition of cancer, or recurrence thereof, (ii) the reduction or elimination of symptoms or cancer cells, (iii) the substantial or complete elimination of cancer, and (iv) the stabilization (i. e. not worsening) of cancer.

[00152] In one example, there is provided the use of a pharmaceutical composition as described herein, comprising for example at least one EZH2 inhibitor, such as DZNep, an antibody, or a siRNA, and at least one IFNGR enhancer such as IFN- γ , in the manufacture of a medicament for the treatment of a patient having cancer. In one embodiment, there is

provided the use of the pharmaceutical composition as described herein, wherein cancer is a metastatic cancer.

[00153] The term "therapeutically effective amount" as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the patient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a daily dosage of between about 0.01 and about 1000 mg/kg body weight per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.1 and about 500 mg/kg body weight, more preferred 0.1 and about 100 mg/kg body weight and most preferred 1.0 and about 10 mg/kg body weight per day. Thus, for administration to a 70 kg person, the dosage range would be about 7 mg to 0.7 g per day. The daily dosage can be administered as a single dosage or in divided dosages, typically between 1 and 5 dosages per day. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect for the individual patient is reached. One of ordinary skill in treating diseases described herein will be able, without undue experimentation and in reliance on personal knowledge, experience and the disclosures of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease and patient.

[00154] In one example, there is provided the method as described herein, wherein said inhibitor is used in a daily dosage of between about 0.01 and about 1000 mg/kg body weight per day. In a further example, the amount of inhibitor is between about 0.1 and about 500 mg/kg body weight, more preferred 0.1 and about 100 mg/kg body weight and most preferred 1.0 and about 10 mg/kg body weight per day. In another example, there is provided the method as described herein, wherein said inhibitor is used in amount of less than 3 mg/kg, or less than 2mg/kg, or less than 1 mg/kg, or less than 0.8 mg/kg, or less than 0.5 mg/kg, or less than 0.2 mg/kg, or between about 0.1 mg/kg to about 3 mg/kg.

[00155] In one example, there is provided the method as described herein, wherein said enhancer is used in an amount of less than 5×10^8 IU/kg, or less than 10^8 IU/kg, or less than 5×10^7 IU/kg, or less than 2×10^7 IU/kg, or less than 10^7 IU/kg, or less than 5×10^6 IU/kg, or

less than 2×10^6 IU/kg, or less than 10^6 IU/kg, or less than 5×10^5 IU/kg, or less than 2×10^5 IU/kg or in an amount of between about 1×10^5 IU/kg to about 10^8 IU/kg of body weight per day. In a further example, there is provided the method as described herein, wherein said enhancer is used in an amount of less than 5×10^6 IU/kg, or less than 10^6 IU/kg, or less than 5×10^5 IU/kg, or less than 2×10^5 IU/kg, or in an amount of between about 1×10^5 IU/kg to about 10^6 IU/kg.

[00156] The compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.

[00157] The compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[00158] The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring.

The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.

[00159] The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[00160] The compounds of the present invention may be formulated for nasal administration. The solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.

[00161] The pharmaceutical composition of the present invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by a metered valve. Alternatively the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). The powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatin or blister packs from which the powder may be administered by means of an inhaler.

[00162] When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient. For example, the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial.

Compounds in transdermal delivery systems are frequently attached to a skin-adhesive solid support. The compound of interest can also be combined with a penetration enhancer, e.g., Azone (1-dodecylaza-cycloheptan-2-one). Sustained release delivery systems are inserted subcutaneously into to the subdermal layer by surgery or injection. The subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polyactic acid.

[00163] The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (salt formulation, esterification, etc.), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

[00164] Formulations

[00165] Pharmaceutical preparations for delivery by various routes are formulated as shown in the following tables. "Active ingredient" or "active compound" as used in the tables means at least one EZH2 inhibitors and at least one INF-gamma receptor enhancer of the pharmaceutical composition.

[00166] Composition for Oral Administration

<i>Ingredient</i>	<i>% wt./wt.</i>
Active ingredient	20.0%
Lactose	79.5%
Magnesium stearate	0.5%

[00167] The ingredients are mixed and dispensed into capsules containing about 100 mg each; one capsule would approximate a total daily dosage.

[00168] Composition for Oral Administration

<i>Ingredient</i>	<i>% wt./wt.</i>
Active ingredient	20.0%
Magnesium stearate	0.5%
Crosscarmellose sodium	2.0%
Lactose	76.5%
PVP (polyvinylpyrrolidone)	1.0%

[00169] The ingredients are combined and granulated using a solvent such as methanol. The formulation is then dried and formed into tablets (containing about 20 mg of active compound) with an appropriate tablet machine.

5 [00170] Composition for Oral Administration

<i>Ingredient</i>	<i>% wt./wt.</i>
Active ingredient	1.0 g
Magnesium stearate	0.5%
Crosscarmellose sodium	2.0%
Lactose	76.5%
PVP (polyvinylpyrrolidone)	1.0%

<i>Ingredient</i>	<i>Amount</i>
Active compound	1.0 g
Fumaric acid	0.5 g
Sodium chloride	2.0 g
Methyl paraben	0.15 g
Propyl paraben	0.05 g
Granulated sugar	25.5 g
Sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
Flavoring	0.035 ml
Colorings	0.5 mg
Distilled water	q.s. to 100 ml

[00171] The ingredients are mixed to form a suspension for oral administration.

[00172] Parenteral Formulation

<i>Ingredient</i>	<i>% wt./wt.</i>
Active ingredient	0.25 g
Sodium Chloride	qs to make isotonic
Water for injection	100 ml

[00173] The active ingredient is dissolved in a portion of the water for injection. A sufficient quantity of sodium chloride is then added with stirring to make the solution

isotonic. The solution is made up to weight with the remainder of the water for injection, filtered through a 0.2 micron membrane filter and packaged under sterile conditions.

[00174] Suppository Formulation

<i>Ingredient</i>	<i>% wt./wt.</i>
Active ingredient	1.0%
Polyethylene glycol 1000	74.5%
Polyethylene glycol 4000	24.5%

- 5 [00175] The ingredients are melted together and mixed on a steam bath, and poured into molds containing 2.5 g total weight.

[00176] Topical Formulation

<i>Ingredients</i>	<i>Grams</i>
Active compound	0.2-2
Span 60	2
Tween 60	2
Mineral oil	5
Petrolatum	10
Methyl paraben	0.15
Propyl paraben	0.05
BHA (butylated hydroxy anisole)	0.01
Water	q.s. 100

- 10 [00177] All of the ingredients, except water, are combined and heated to about 60° C. with stirring. A sufficient quantity of water at about 60° C. is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. about 100 g.

[00178] Nasal Spray Formulations

- 15 [00179] Several aqueous suspensions containing from about 0.025-0.5 percent active compound are prepared as nasal spray formulations. The formulations optionally contain inactive ingredients such as, for example, microcrystalline cellulose, sodium carboxymethylcellulose, dextrose, and the like. Hydrochloric acid may be added to adjust pH. The nasal spray formulations may be delivered via a nasal spray metered pump typically

delivering about 50-100 microliters of formulation per actuation. A typical dosing schedule is 2-4 sprays every 4-12 h.

[00180] The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

[00181] The at least two components of the pharmaceutical composition disclosed (i.e. the at least one EZH2 inhibitor and the at least one IFN-gamma receptor enhancer) may be co-administered at the same time (e.g. simultaneously) or at different times (e.g. sequentially) and over different periods of time, which may be separate from one another or overlapping. Where the two components are co-administered simultaneously they may be provided in one or more pharmaceutical compositions. Where the two components are provided in the form of separate compositions the two components may be co-administered separately, sequentially or simultaneously. The two components may be administered in any order but in one example the at least one EZH2 inhibitor is administered prior to the at least one IFN-gamma receptor enhancer.

[00182] In one example, the at least two components of the pharmaceutical compositions may be administered by the same or different routes. For example, the composition is administered locally. In another example as shown in example 6 described below, IFN- γ is administered via intra-peritoneal (I.P) route once daily and DZNep via subcutaneous injection once every 2 days. The present disclosure also envisages administering the compounds systemically. In some instances, the compounds are administered orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularly, intrapericardially, intraperitoneally, intrapleurally, intraprostatically, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularly, intravitreally, liposomally, locally, mucosally, orally, parenterally, rectally, subconjunctivally, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in crèmes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, via localized perfusion, bathing target cells directly, or any combination thereof. For

example, in some variations, the compounds are administered intravenously, intra-arterially or orally. For example, in some variations, the compounds are administered intravenously.

[00183] Where the two components are administered as separate compositions, they may be administered within 120, 96, 84, 72, 48, 36, 24, 12, 6, 3, 2, 1, 0.5, 0.25 or 0.125 hours of each other. For example, EZH2 inhibitor is administered within 84, 72, 48, 36, 24, 12, 6, 3, 2, 1, 0.5, 0.25 or 0.125 hours prior to administration of the IFN- γ receptor enhancer. It may be useful to administer IFN- γ receptor enhancer prior the EZH2 inhibitor to assess the effect of the enhancer on the expression of factors involved, for example in apoptosis, cell cycle arrest, proliferation or any molecular mechanism useful in the treatment of aggressive cancer and thus adapt the amount of drug needed and the EZH2 inhibitor to be used in a given patient. For example, it may be advantageous to administer IFN- γ intraperitoneally and to administer DZNep by subcutaneous injection rather than by intraperitoneal administration to reduce potential adverse effects such as weight loss.

[00184] In one example, there is provided the method as described herein, wherein cancer is metastatic cancer. Since as explained above, metastatic cancers such as for example metastatic prostate cancers, are often refractory to hormonal and surgical treatments, it may be advantageous to treat metastatic cancer with the pharmaceutical composition of the invention. In one example, the method as described herein can be used for treating prostate cancer, such as for example, metastatic prostate cancer. In another example, there is provided the methods as described herein, wherein cancer includes but is not limited to liver, ovarian, lung, acute lymphoblastic leukemia, breast particularly luminal B breast, bladder, and lymphoma mantle-cell cancer. In some embodiments, the cancer treated or prevented in the invention may be any form of a cancer. Any forms of tumor or cancer may be used in the invention including for example, a benign tumor and a metastatic malignant tumor. Examples of cancers include, but are not limited to, gastric cancer, colon cancer, lung cancer, breast cancer, bladder cancer, neuroblastoma, melanoma, head and neck cancer, esophagus cancer, cervix cancer, prostate cancer and leukemia.

[00185] Other examples of tumors include, but are not limited to, haematological malignancies and solid tumours. Solid tumours include for instance a sarcoma, arising from connective or supporting tissues, a carcinoma, arising from the body's glandular cells and epithelial cells or a lymphoma, a cancer of lymphatic tissue, such as the lymph nodes, spleen, and thymus.

[00186] Other cancers that can be envisaged to be treated by the method of the invention are solid tumours. As indicated above, the present disclosure is partially based on the unexpected discovery that in some cancer cell lines, tissue isolated from patient with cancer or, a tumor sample isolated from a patient having cancer the levels of EZH2 is increased and the level of INFG1 is decreased. One skilled in the art would be able to determine the level of the mRNA, cDNA or proteins (e.g. EZH2 or INFG1) by techniques such as for example, RT-PCR, microarrays, ChIPs, immunofluorescence or western blot.

[00187] Thus, in one example, there is provided the method as described herein wherein the patient is characterized by an increased level of EZH2 in a tumor sample and a decreased level of IFNG1 in a tumor sample. As presently shown by the inventors, a tumor cell, a tumour sample tissue or a whole organism having cancer wherein the level of EZH2 is increased and IFNG1 is decreased as compared to a normal (or non-tumour) cell, normal (or non-tumour) tissue or healthy (non-cancerous) organism.

[00188] As used herein, the expression "gene upregulated in cancer" or a gene with "increased level" refers to a gene that is expressed (e.g., mRNA or protein expression) at a higher level in cancer (e.g., prostate cancer) relative to the level in other tissues. In some embodiments, genes upregulated in cancer are expressed at a level at least 10%, preferably at least 25%, even more preferably at least 50%, still more preferably at least 100%, yet more preferably at least 200%, and most preferably at least 300% higher than the level of expression in other tissues.

[00189] As used herein, the term "gene downregulated in cancer" or a gene with "decreased level" refers to a gene that is expressed (e.g., mRNA or protein expression) at a lower level in cancer tissue relative to the level in other tissue. In some embodiments, genes downregulated in cancer tissue are expressed at a level at least 10%, preferably at least 25%, even more preferably at least 50%, still more preferably at least 100%, yet more preferably at least 200%; and most preferably at least 300% lower than the level of expression in other tissues.

[00190] As used herein, the term "subject" refers to any animal (e.g., a mammal), including, but not limited to, humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment. Typically, the terms "subject" and "patient" are used interchangeably herein in reference to a human subject. A "therapeutic" compound as defined herein is a compound (or an agent or a molecule or a composition) capable of acting

prophylactically to prevent the development of a weakened and/or unhealthy state; and/or providing a subject with a sufficient amount of the complex or pharmaceutical composition or medicament thereof so as to alleviate or eliminate a disease state and/or the symptoms of a disease state, and a weakened and/or unhealthy state. In one example, the therapeutic compound includes but is not limited to an apoptosis promoting compound, a
5 chemotherapeutic compound or a compound capable of alleviating or eliminating cancer in a patient.

[00191] The term "treat" or "treating" as used herein is intended to refer to providing an pharmaceutically effective amount of a peptide of the present invention or a respective
10 pharmaceutical composition or medicament thereof, sufficient to act prophylactically to prevent the development of a weakened and/or unhealthy state; and/or providing a subject with a sufficient amount of the complex or pharmaceutical composition or medicament thereof so as to alleviate or eliminate a disease state and/or the symptoms of a disease state, and a weakened and/or unhealthy state.

[00192] Based on the above, there is provided a method for determining susceptibility of a patient suffering from cancer to a treatment with a pharmaceutical composition as defined herein, wherein the method comprises comparing a first level of EZH2, including but not limited to, EZH2 mRNA level in a tumor sample, EZH2 cDNA level made from mRNA from said tumor sample, and EZH2 protein level from said tumor sample, with a second level of
20 EZH2 including but not limited to, EZH2 mRNA level from a non-tumor sample from said patient, EZH2 cDNA level made from mRNA from said non-tumor sample, and EZH2 protein level from said non-tumor sample; comparing a first level of IFNGR1 including but not limited to, IFNGR1 mRNA level from said tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample
25 with the level of IFNGR1, including but not limited to, IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample; and wherein a patient characterized by an increased level of EZH2 in said tumor sample and a decreased level of IFNGR1 in said tumor sample is susceptible to a treatment with said pharmaceutical
30 composition. Advantageously, the experimental results presented herein allowed the identification of for example, EZH2 and INFGR1, as potential therapeutic targets for the pharmaceutical composition as described herein. The term "susceptibility" in the context of

the present invention refers to a patient's ability to be responsive to anti-cancer treatment, and relates to the presence or absence of EZH2 and IFNGR1.

[00193] Hence, in one example, there is provided a method for treating cancer in a patient with a difference in the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein in a tumor sample, and the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein from a non-tumor sample, wherein the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein are at least 2-fold higher in the tumor sample and the IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein level is at least 2-fold lower in the tumor sample, wherein the method comprises administration of a pharmaceutical composition as described herein to the patient. As explained above, there is an inverted correlation between the levels of EZH2 and IFNGR1 in patients having cancer or suspected to have cancer, making them more susceptible to treatment with the pharmaceutical compositions as described herein. The difference between the normalized levels of mRNAs, cDNAs or proteins between the tumour and non-tumour sample, is ideally no less than about 1.2- fold difference (higher or lower as indicated above, no less than about 1.2- fold no less than about 1.4- fold difference, no less than about 1.5- fold difference, no less than about 1.7- fold difference, no less than about 1.9- fold difference, no less than about 2- fold difference, no less than about 3- fold difference, no less than about 5- fold difference or no less than about 10- fold difference. In another example, there is provided the use of a pharmaceutical composition as described herein in the manufacture of a medicament for treating cancer in a patient with a difference in the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein in a tumor sample, and the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein from a non-tumor sample, wherein the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein are at least 2-fold higher in the tumor sample and the IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein level is at least 2-fold lower in the tumor sample.

[00194] In one example, there is provided a method for treating cancer in a patient with a difference in the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein in a tumor sample, and the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA,

and/or IFNGR1 cDNA, and/or IFNGR1 protein from a non-tumor sample, wherein the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein are at least 2-fold higher in the tumor sample and the IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein level is at least 2-fold lower in the tumor sample, wherein the method comprises administration of a pharmaceutical composition as described herein, to the patient. In another example, there is provided the use of a pharmaceutical composition as described herein in the manufacture of a medicament for treating cancer in a patient with a difference in the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein in a tumor sample, and the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein from a non-tumor sample, wherein the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein are at least 2-fold higher in the tumor sample and the IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein level is at least 2-fold lower in the tumor sample.

[00195] In another example, there is provided the method (or the medicament, or the pharmaceutical composition) as described herein, wherein the cancer comprises but is not limited to, prostate, liver, ovarian, lung, acute lymphoblastic leukemia, breast particularly luminal B breast, bladder, and lymphoma mantle-cell cancer. Based on the experimental results described herein, it may be possible to determine that patients having a tumor or suspected to have cancer, with a normalized high level of EZH2 and a normalized low level of IFNGR1 as compared to the levels of EZH2 and IFNGR1 in a corresponding tissue of a healthy subject, will respond efficiently to treatment with a pharmaceutical composition as described herein.

[00196] In one example, there is provided the method as described herein, wherein the first level of EZH2 protein from said tumor sample and the second level of EZH2 protein from said non-tumor sample, and wherein a first level of IFNGR1 protein from said tumor sample with the level of IFNGR1 protein from said non-tumor sample is examined by immunohistochemistry. The method includes the use of antibodies or fragments thereof directed against an antigen comprised in the EZH2 and the IFNGR1 proteins, and the use of secondary antibodies that have been modified with detectable moieties, such as for example, fluorescent, luminescent, chemiluminescent or radioactive moieties. The examination by immunochemistry should allow the skilled person in the art to quantify and normalize the

amount of protein in the tumor sample and the non-tumor sample, in order to be able to compare the levels of proteins.

[00197] In another example, there is provided the method as described herein, wherein the level of EZH2 expression from said tumor sample and from said non-tumor sample, and
5 wherein the level of IFNGR1 expression from said tumor sample and from said non-tumor sample is examined by q-PCR, wherein q-PCR comprises selecting primers comprising but not limited to primers having the nucleic acid sequences of SEQ ID No's 3 to 34. The person in the skilled art may select some primers to perform a quantitative polymerase chain reaction in order to be able to compare the expression levels of genes of interest in a tumour and a
10 non-tumour sample.

[00198] In a further example, the present disclosure provides a method for determining susceptibility of a patient suffering from advanced prostate cancer to a treatment with a pharmaceutical composition as defined herein, wherein the method comprises comparing a first level of IFNGR1, including but not limited to, IFNGR1 mRNA level in a tumor sample,
15 IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1, including but not limited to, IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample; and wherein a patient characterized by a decreased level of IFNGR1 in said tumor sample is
20 susceptible to a treatment with said pharmaceutical composition.

[00199] In one example, there is provided a method for determining susceptibility of a patient suffering from breast cancer to a treatment with a pharmaceutical composition as defined herein, wherein the method comprises comparing a first level of IFNGR1, including but not limited to, IFNGR1 mRNA level in a tumor sample, IFNGR1 cDNA level made from
25 mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1, including but not limited to, IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample; wherein a patient suffering from basal breast cancer is characterized by an increased level of INFGR1 in said tumor
30 sample is not susceptible to a treatment with said pharmaceutical composition ; and wherein a patient suffering from luminal breast cancer is characterized by a decreased level of INFGR1 in said tumor sample is susceptible to a treatment with said pharmaceutical composition.

[00200] In one example, there is provided a method for making a prognosis with respect to the clinical outcome of a patient suffering from cancer comprising comparing a first level of EZH2, including but not limited to, EZH2 mRNA level in a tumor sample, EZH2 cDNA level made from mRNA from said tumor sample, and EZH2 protein level from said tumor sample, with a second level of EZH2, including but not limited to, EZH2 mRNA level from a non-tumor sample from said patient, EZH2 cDNA level made from mRNA from said non-tumor sample, and EZH2 protein level from said non-tumor sample; comparing a first level of IFNGR1, including but not limited to, IFNGR1 mRNA level from said tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1, including but not limited to, IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample; and making a prognosis with respect to the clinical outcome of a patient suffering from cancer. In a further example, there is provided the method as defined above, wherein said clinical outcome indicates the susceptibility to treatment with said pharmaceutical composition as defined herein. In another example, there is provided the method as defined herein, wherein the cancer, can include but is not limited to, prostate, liver, ovarian, lung, particularly small cell lung, leukemia, particularly acute lymphoblastic leukemia, breast particularly luminal B breast, bladder, or lymphoma mantle-cell cancer.

20

EXPERIMENTAL SECTION

[00201] **Example 1**

[00202] **MYC or PI3K-mediated oncogenic transformation in prostate epithelial cells induces transcriptional inactivation of IFN- γ -JAK-STAT1 signaling**

[00203] Gene amplification of MYC or constitutive activation of PI3K signaling pathway occurs frequently in advanced prostate cancer. To investigate the molecular events induced by MYC or PI3K, immortalized prostate epithelial RWPE cells were used and infected them with retroviral *MYC* or a constitutively activating mutant of *PIK3CA* (E545K), resulting in transformed cell lines showing elevated level of MYC or AKT phosphorylation, designated as RWPE1-MYC, and RWPE1-PI3K, respectively (Fig. 8 and Fig. 2C).

30

[00204] As oncogenic transformation is often coupled with epigenetic gene silencing, gene expressing profiling was performed and the focus was on pathways and gene sets that are

downregulated upon oncogenic transformation. Among 610 genes differentially expressed (with 2-fold cutoff, $P < 0.01$), a set of 344 genes were identified that was downregulated in both RWPE1-MYC and RWPE1-PI3K cells as compared with the empty vector control RWPE1 cells (Fig. 1A, Table 2). Ingenuity Pathway Analysis (IPA) indicates that this gene set was enriched for canonical interferon signaling as the top gene network ($P < 3 \times 10^{-11}$) (Fig. 1B).

[00205] Furthermore, 63 out of 344 genes commonly downregulated in MYC- and PI3K-activated cell lines were identified as interferon responsive genes (IFN genes) in the INTERFEROME database (Fig. 1C), which can be mapped at multiple levels in the IFN-JAK-STAT1 signaling cascade (Fig. 1D, highlighted in green). Notably, *IFNGR1*, which encodes the interferon γ receptor 1, was downregulated, while *IFNARI*, which encodes the interferon $\alpha 1$ receptor, was not (Fig. 1D). Thus, these findings suggest that MYC or PI3K activation in prostate epithelial cells may have induced a transcriptional inactivation of IFN-signaling, which is specific for *IFNGR1*, but not *IFNARI*.

[00206] Downregulation of interferon γ receptor (*IFNGR1*) expression is expected to cause reduced response to IFN- γ stimulation, leading to impaired activation of JAK-STAT1 activity. Indeed, IFN- γ -induced phosphorylation of JAK2 and STAT1 transcriptional activity, as measured by an ELISA-based assay and a STAT1-mediated luciferase reporter assay respectively, were much reduced in both RWPE1-MYC and RWPE1-PI3K cells as compared to the control RWPE1 cells (Fig. 1E and F).

[00207] Consistently, western blotting confirms the downregulation of IFNGR1 protein expression and dampened induction of STAT1 Tyr701 phosphorylation in response to IFN- γ treatment in RWPE1-MYC and RWPE1-PI3K cells as compared with the RWPE1 cells (Fig. 1G). Quantitative RT-PCR (qRT-PCR) analysis further validated the gene expression array data by showing the down regulation of *IFNGR1* and various *IFN* downstream genes in both MYC- and PI3K-transformed RWPE1 cells (Fig. 1H). Importantly, the downregulation of *IFNGR1* (but not *IFNARI*) and the downstream *IFN* responsive genes were also found in a panel of prostate cancer cell lines (Fig. 1I).

Table 2: Downregulated genes expressed in terms of fold difference in either RWPE1-MYC or RWPE1-PI3K cells with a cut-off of <-2 after normalizing against the vector control RWPE1 cells.

Symbol	RWPE1		
	Vector	PI3K (E545K)	MYC
IFI27	1	-17.8743	-73.0761
IFI6	1	-16.5152	-40.9701
IFI44L	1	-16.4912	0
KLK5	1	-15.3243	0
RSAD2	1	-14.7267	0
XAF1	1	-13.6573	0
KLK5	1	-13.4396	-28.0406
MX2	1	-10.6677	0
OAS2	1	-9.71016	0
OAS1	1	-9.6326	0
CLDN1	1	-9.53868	-12.4893
EPSTI1	1	-8.94257	-24.3219
RARRES3	1	-8.77149	0
S100P	1	-7.93449	-1.09225
XAF1	1	-7.60302	-11.5538
TRIM22	1	-7.42753	-16.0546
LAMP3	1	-7.11102	-5.8311
HERC6	1	-7.07562	-20.6502
SNRPN	1	-6.85279	-1.59023
MX1	1	-6.83834	-98.8357
TNFSF10	1	-6.24743	-12.7431
CCL2	1	-6.14527	0
CRIP1	1	-6.0692	-4.90306
IFIT3	1	-6.01677	-39.1901
SAMD9	1	-5.89703	-13.0126
ISG15	1	-5.73126	-16.4992
STAT1	1	-5.59124	-18.4787
RPS4Y1	1	-5.56669	1.485994
OAS2	1	-5.49693	0
DDX60	1	-5.44447	-16.8777
BTBD11	1	-5.42183	-3.77361
ECGF1	1	-5.38314	-6.2397
IFIT1	1	-5.31675	-31.9666
IFIT3	1	-5.30808	0
CXCL10	1	-5.25124	-7.99236
ZIC2	1	-5.23106	-4.08437
IFITM1	1	-5.13859	-10.2944

FOXQ1	1	-5.10141	-9.38273
PNLIPRP3	1	-5.0611	0
SERPINA3	1	-5.02867	-5.9415
SAMD9L	1	-4.99383	0
AKR1B10	1	-4.96005	0
MXRA5	1	-4.93851	-5.07588
OAS1	1	-4.92301	-6.837
MKX	1	-4.88046	-4.90035
OAS2	1	-4.86569	0
OASL	1	-4.79873	-18.0583
ALDH3A1	1	-4.7885	-4.68453
KRT15	1	-4.74698	-13.4386
DDX58	1	-4.62593	-8.44421
IFIT2	1	-4.53772	-23.129
IFI44	1	-4.5224	-33.3923
OAS1	1	-4.45264	-6.51132
CTGF	1	-4.44726	-16.4104
STAT1	1	-4.44203	-14.4979
SNRPN	1	-4.44051	-1.1559
UGT1A6	1	-4.37973	-5.34731
IRF7	1	-4.36642	-7.12519
DHRS3	1	-4.34558	-2.30335
KLK10	1	-4.32362	-5.64646
FAM43A	1	-4.29989	-2.4056
SDPR	1	-4.28703	-3.76978
SGK	1	-4.26917	-17.862
UGT1A6	1	-4.22413	-4.91623
RNF150	1	-4.16771	0
GBP1	1	-4.09511	-7.4659
CDH13	1	-4.09377	-1.81876
RPS4Y2	1	-4.07922	1.789499
ID1	1	-4.07902	-1.19702
IGFBP6	1	-4.02618	-3.19651
PRICKLE1	1	-4.01465	-3.25904
FRAS1	1	-3.98435	-1.06816
GPRC5C	1	-3.94143	-2.20771
TSHZ2	1	-3.93678	0
SP110	1	-3.92097	-8.33054
TSHZ3	1	-3.89158	0
IRF7	1	-3.88008	-5.31077
TFCP2L1	1	-3.79911	-5.64592
KLHDC8B	1	-3.70366	-2.18648
IFIH1	1	-3.65978	-8.78613

NEBL	1	-3.64006	-2.75499
PDK4	1	-3.63403	0
P8	1	-3.62499	-1.07519
NCOA7	1	-3.62028	-3.14289
OASL	1	-3.6186	0
SFRP1	1	-3.60717	-3.33534
ADRB2	1	-3.6005	-7.32535
PRRG2	1	-3.58798	-2.16193
IRF1	1	-3.54903	-4.88511
SP110	1	-3.54245	-8.60818
NFIX	1	-3.49562	-4.27031
HSH2D	1	-3.49469	-6.57252
NUPR1	1	-3.47694	-1.1016
AUTS2	1	-3.44727	-5.80848
CH25H	1	-3.44105	0
MME	1	-3.42257	-3.38259
CEL	1	-3.38582	-1.97371
SLC1A3	1	-3.38279	-2.55169
OAS3	1	-3.37572	-4.84003
P2RY5	1	-3.36923	-3.10518
GBP4	1	-3.32848	-3.72049
SUSD2	1	-3.32179	0
STAT1	1	-3.317	-7.77765
HERC5	1	-3.30749	-26.7293
ELF3	1	-3.28097	-4.19081
RAET1G	1	-3.27051	-1.1041
HES4	1	-3.26397	-2.1495
IL6	1	-3.25509	-3.73924
PLSCR1	1	-3.25128	-5.09925
NOTCH1	1	-3.24542	-1.5392
PARP9	1	-3.23719	-4.95694
AKR1C2	1	-3.22758	-2.09065
CALML3	1	-3.21559	-3.42797
PRIC285	1	-3.20522	-7.484
RND3	1	-3.20391	-2.99375
CPS1	1	-3.18838	1.33824
NINJ1	1	-3.16788	-1.44584
COL8A1	1	-3.15052	-7.55795
SNCA	1	-3.14852	-2.52501
UBE2H	1	-3.13817	-2.5673
PTPRM	1	-3.12065	1.918932
IRF9	1	-3.11836	-13.022
AHNAK	1	-3.11139	-2.56856

S1PR3	1	-3.09794	-4.16193
COL8A1	1	-3.09684	0
NAV2	1	-3.0429	-1.5603
AHNAK	1	-3.01399	-2.70158
SP100	1	-3.00103	-3.7716
FXVD3	1	-2.98965	-3.21165
STARD5	1	-2.98829	-3.84417
SP100	1	-2.98761	-3.236
PTGER4	1	-2.9803	-3.35191
COL5A1	1	-2.97542	-3.3449
CGNL1	1	-2.95599	0
DLL1	1	-2.95361	-4.96959
HAS3	1	-2.93598	-4.85051
TLE4	1	-2.92651	-2.38054
FBXO2	1	-2.91668	-3.50251
C15orf48	1	-2.91543	-1.73605
FBXO32	1	-2.874	-2.99236
TSC22D3	1	-2.8608	-2.28563
IL13RA2	1	-2.85721	-3.26831
C1QTNF1	1	-2.85168	-1.1121
SNCA	1	-2.84333	-2.18968
KLF4	1	-2.82996	1.191471
PLTP	1	-2.81382	1.667983
ECM2	1	-2.81232	2.447139
C5orf23	1	-2.80702	-1.66034
MATN2	1	-2.80379	-3.7195
IFI35	1	-2.78241	-8.54067
GDF15	1	-2.78075	1.20734
PDZD2	1	-2.77311	-4.37154
LRIG1	1	-2.77302	-2.75495
PARP10	1	-2.76716	-3.58787
EFEMP1	1	-2.73839	-12.8271
ABCA1	1	-2.73342	-1.93387
SPOCK1	1	-2.73079	1.300084
TAP1	1	-2.72792	-2.95213
PARP12	1	-2.72389	-3.21894
C14orf159	1	-2.66409	-2.1711
H1FO	1	-2.66232	-3.18551
PDPN	1	-2.65938	1.228458
NNMT	1	-2.64692	-5.21434
C1orf116	1	-2.6387	-6.05598
TRMT1	1	-2.62477	-1.93189
MDK	1	-2.61659	-2.24699

CA12	1	-2.61268	1.295919
DKK3	1	-2.61203	-5.73642
FAM46B	1	-2.60997	-5.69141
IFNGR1	1	-2.60734	-2.75367
LAP3	1	-2.6027	-1.91627
CFB	1	-2.60197	-5.86999
GAMT	1	-2.59296	-2.24434
TDRD7	1	-2.58147	-8.24047
AKR1C3	1	-2.54231	-3.72025
CEACAM1	1	-2.54059	0
ARMCX2	1	-2.52824	1.293912
SCD5	1	-2.52258	-2.11499
DKK3	1	-2.51378	-5.36429
UBE2L6	1	-2.51067	-6.74206
TM4SF1	1	-2.48929	-5.70556
SLC43A3	1	-2.48614	1.166472
EFEMP1	1	-2.48131	-13.2097
C9orf3	1	-2.47376	-1.63753
ZBTB16	1	-2.47129	-4.49531
BCL6	1	-2.46016	-3.94866
APOL3	1	-2.45744	-3.05898
CYP2J2	1	-2.4506	-4.44102
IL8	1	-2.4491	-2.62036
TSC22D3	1	-2.44766	-2.04666
CCL5	1	-2.44673	-9.50327
MAP2	1	-2.44317	-2.51548
C19orf66	1	-2.43681	-4.961
FXVD3	1	-2.4298	-2.58134
CPA4	1	-2.42461	0
LMO2	1	-2.42267	-2.60662
PID1	1	-2.42209	-4.08724
D4S234E	1	-2.42147	-3.22768
RBBP8	1	-2.42131	-2.37137
STX10	1	-2.41265	-1.98528
EFEMP1	1	-2.40053	-4.27066
TRIM21	1	-2.40041	-4.2023
UBE2L6	1	-2.39853	-3.83604
KITLG	1	-2.38863	-2.18432
MN1	1	-2.38314	-1.2506
DPYSL3	1	-2.37977	1.278269
ISG20	1	-2.36002	-7.67305
PSMB9	1	-2.35768	-7.74624
NT5E	1	-2.35693	-3.01737

APOE	1	-2.35637	-2.71449
FBLN1	1	-2.3551	-4.2408
UBA7	1	-2.35421	0
SOD2	1	-2.35192	-2.40564
PROS1	1	-2.33164	-3.33977
HBEGF	1	-2.32723	1.632474
LPHN1	1	-2.31898	2.72042
CXCL2	1	-2.31796	-3.233
TMEM156	1	-2.30881	-1.49085
ZNFX1	1	-2.30577	-4.00188
SSBP2	1	-2.30116	-2.59611
VAMP5	1	-2.2968	-3.18909
MBP	1	-2.27955	-1.22528
ZC3HAV1	1	-2.27785	-4.22738
IRS2	1	-2.27749	-2.3939
SAA1	1	-2.27607	-7.09373
LIMCH1	1	-2.25982	-4.10693
IRX4	1	-2.24545	-3.35408
H19	1	-2.23655	-7.11566
KCNMA1	1	-2.23573	-2.1332
ALDH3A2	1	-2.23002	-2.51574
GAMT	1	-2.22638	-2.09051
CRYAB	1	-2.22188	-2.19121
DHX58	1	-2.19676	-3.48679
ENC1	1	-2.17211	-2.89626
PARP14	1	-2.16842	-4.22674
HTRA1	1	-2.15993	-2.42448
C10orf59	1	-2.15484	1.108868
TFPI	1	-2.1438	-4.71083
PODXL	1	-2.13888	1.806846
ETS2	1	-2.12799	-1.95914
DHRS2	1	-2.11015	-3.003
IGFBP4	1	-2.09946	-1.21718
C10orf54	1	-2.09598	-2.94343
CFH	1	-2.08862	-2.49672
FLRT2	1	-2.0816	-1.15986
FOXA1	1	-2.08024	-3.46667
C1S	1	-2.07987	-2.95596
NPTX2	1	-2.06893	1.557073
ATF3	1	-2.06752	1.07467
KRT13	1	-2.05874	-2.62563
AOX1	1	-2.05855	0
CDH11	1	-2.05177	-3.59808

TNFRSF14	1	-2.04958	-1.71062
STAT2	1	-2.04954	-4.87075
SLC43A3	1	-2.04937	1.417271
NOTCH3	1	-2.04889	5.393062
PHF11	1	-2.03569	-2.45454
STS-1	1	-2.02838	-1.35028
EIF2AK2	1	-2.02668	-3.49876
IFITM2	1	-2.02407	-3.87637
KLF6	1	-2.01916	-1.84199
BASP1	1	-2.00465	-1.86717
OSBP2	1	-1.97101	-3.60314
LEPREL1	1	-1.96294	-5.84162
SOD2	1	-1.93428	-2.33246
PLAC8	1	-1.93272	-10.2138
PHF11	1	-1.91247	-2.45303
PIK3R1	1	-1.89025	-3.47858
CBR3	1	-1.86845	-3.24695
SAA1	1	-1.86567	-8.07595
MYADM	1	-1.84083	-2.38509
REC8	1	-1.8097	-2.54367
PRSS23	1	-1.80801	-2.5119
KRT14	1	-1.8055	-3.95635
KRT19	1	-1.80052	-5.97256
LY6E	1	-1.79411	-2.31856
SAA2	1	-1.78685	-5.57727
HRASLS3	1	-1.78336	-3.9676
ZNF256	1	-1.78203	-3.42712
GALNT10	1	-1.77767	-2.05615
ZSCAN18	1	-1.7735	-5.8675
DPYD	1	-1.75581	-2.85288
TMEM40	1	-1.7444	-3.29025
ASCL2	1	-1.74426	-3.7976
FEZ1	1	-1.73308	-2.00585
FAM46A	1	-1.7221	-3.39868
TACSTD2	1	-1.72204	-4.46011
ARID5B	1	-1.69279	-4.48695
HCP5	1	-1.68987	-5.48799
LPXN	1	-1.68657	-2.39644
IFITM3	1	-1.68021	-3.37424
ZBTB16	1	-1.64861	-2.35628
PPP1R3C	1	-1.63292	-3.31748
FOS	1	-1.62189	-2.43906
IGFBP7	1	-1.55948	-4.80971

NMI	1	-1.55433	-3.49245
FAM111A	1	-1.54744	-3.2378
RAB7B	1	-1.53697	-3.0797
EPDR1	1	-1.50587	-3.14162
CLIC3	1	-1.49496	-3.21748
KRT5	1	-1.47614	-3.16513
C1RL	1	-1.45983	-2.57394
PSMB8	1	-1.43906	-2.4564
EMP1	1	-1.43275	-3.40126
CAV2	1	-1.41908	-2.50767
LOX	1	-1.40002	-2.6319
PSMB8	1	-1.39608	-2.53212
PSMB8	1	-1.39003	-2.11675
DNER	1	-1.37583	-2.12381
CASP1	1	-1.36673	-4.60663
BST2	1	-1.31658	-5.99401
SAA1	1	-1.30334	-2.97076
C1orf225	1	-1.29701	-2.264
ABCC3	1	-1.29217	-3.06003
KRT16	1	-1.27737	-2.12919
SQRDL	1	-1.27004	-2.71467
S100A8	1	-1.25056	-5.09928
CASP1	1	-1.2314	-4.31351
SLC47A2	1	-1.21808	-2.47908
OPTN	1	-1.21739	-2.3348
TFAP2C	1	-1.21697	-4.82067
TIMP2	1	-1.2166	-3.20078
PLEKHA4	1	-1.14712	-2.10986
IRS1	1	-1.09989	-2.04009
ARHGDIB	1	-1.0664	-4.20726
C1orf53	1	-1.05763	-2.70324
FAM134B	1	0	-4.58487
HOXA5	1	1.035466	-3.57871
FST	1	1.091432	-3.08217
FST	1	1.096288	-8.719
S100A9	1	1.110295	-2.93526
IL1B	1	1.110625	-2.09728
ADM	1	1.135267	-4.52446
CAMK2B	1	1.230406	-2.28352
IFI16	1	1.242815	-5.96296
KIF20A	1	1.299295	-2.39991
ZNF415	1	1.30571	-3.33475
FGFBP1	1	1.572931	-8.86766

C10orf116	1	1.597527	-2.28262
ADFP	1	1.638751	-3.57931
PI3	1	1.705046	-2.77734
RRAGD	1	1.825306	-3.24677
C1orf115	1	2.042584	-2.0006
PHACTR3	1	3.263027	-2.71081

[00208] **Example 2**

[00209] ***IFNGR1* is a direct target of EZH2 in MYC-driven, but not PI3K-driven prostate cancer cells**

5 [00210] The mechanism of loss of *IFNGR1* and its downstream IFN responsive genes could result from epigenetic modifications such as DNA methylation or histone modifications. Given a well-known role of EZH2 in advanced prostate cancer, and that both *MYC* and PI3K signaling have been recently shown to regulate EZH2 expression or activity, the possible role of EZH2 in control of IFN signaling was investigated in *MYC* and *PI3K*-
10 transformed cells. To this end, it was found that the ectopic overexpression of EZH2 in RWPE1 cells is able to selectively downregulate *IFNGR1* (but not *IFNARI*) and other IFN responsive genes (Fig. 2A). Notably, in RWPE1-MYC cells, *EZH2* knockdown was able to restore the expression of *IFNGR1* (but not *IFNARI*), which however was not seen in RWPE1-PI3K cells (Fig. 2B). Thus, EZH2 appears to be involved in *IFNGR1* repression only
15 in MYC-driven cells, but not in PI3K-driven cells.

[00211] *MYC* has been previously known to upregulate EZH2 expression via downregulating miR-26a/b. It has also been recently shown to affect EZH2 activity by antagonizing PI3K-AKT-mediated phosphorylation of EZH2 on serine 21. Akt-induced EZH2 phosphorylation on serine 21 is inhibitory to EZH2 gene silencing activity but
20 promotes its Polycomb-independent oncogenic activity. Indeed, we found that MYC-driven RWPE cells showed concurrent reductions of phosphorylation on both AKT (S473) and EZH2 (S21) as compared with PI3K-driven cells (Fig. 2C). Meanwhile, *MYC* overexpression only led to a modest decrease in miR-26a, and consistently a modest induction of EZH2 mRNA level (Fig. 9A and B). These findings suggest that *MYC* overexpression in our system
25 more likely modulates the EZH2 activity through counteracting AKT-mediated EZH2 inhibition, rather than through miR-26a-mediated mechanism.

[00212] Next, we investigated whether EZH2 directly represses *IFNGR1* as well as the downstream IFN genes. Chromatin immunoprecipitation (ChIP) followed by quantitative

PCR analysis in the vicinity of the promoter region of *IFNGR1* (Fig. 2D) shows significant EZH2 enrichments in RWPE1-MYC cells (Fig. 2E, compared with the positive control gene *CNRI*), but not in RWPE1-PI3K and the vector control RWPE cells (Fig. 2E). In addition, no EZH2 enrichment was found in genes downstream of *IFNGR1* (Fig. 9C). Therefore, the transcriptional inactivation of IFN-JAK-STAT1 signaling seen in MYC-driven cells may stem from a direct suppression of *IFNGR1* by EZH2.

[00213] Similar to transformed RWPE1-MYC cells, we found a significant EZH2 enrichments in the *IFNGR1* promoter in two prostate cancer cell lines, DU145 and PC3 which have been previously known to carry MYC amplification or sensitive to MYC inhibition, but not in LNCaP and 22RV1 cells which are less sensitive to MYC knockdown, and thus appeared to be MYC-independent (Fig. 2F, Fig. 9D). Furthermore, *MYC* knockdown in DU145 cells resulted in much reduced enrichments of both EZH2 and H3K27me3 in the *IFNGR1* promoter (Fig. 2G), which however was not seen in LNCaP cells. This data further supports that EZH2-mediated silencing of *IFNGR1* is MYC-dependent.

[00214] In addition, we found a partial DNA hypermethylation in the *IFNGR1* promoter in RWPE1-PI3K cells and LNCaP cells but not in RWPE1-MYC and DU145 cells (Fig. 9E). Thus, using both transformed RWPE1 cells and prostate cancer cell lines we conclude that EZH2-mediated repression of *IFNGR1* is restricted to MYC-associated prostate cancer cells, while the *IFNGR1* downregulation in PI3K-transformed RWPE1 or LNCaP cells is independent of EZH2, and might be associated with the promoter DNA hypermethylation.

[00215] Example 3

[00216] *IFNGR1* is downregulated in a subset of metastatic prostate tumors associated with *MYC*

[00217] To validate the *IFNGR1* downregulation in clinical samples, we examined the expression of *IFNGR1*, together with *MYC* and *EZH2* in a previously published prostate cancer gene expression dataset which covers the disease progression from benign prostatic epithelium to metastatic prostate cancer. We found that a subset of metastatic tumors show strong upregulations of *MYC* and *EZH2*, while *IFNGR1* and the downstream IFN genes were downregulated towards the metastatic progression (Fig. 3A).

[00218] Moreover, when these tumors were stratified based on the *MYC* levels, we found that high *MYC* tumors tend to express higher levels of EZH2 and lower levels of *IFNGR1*

(Fig. 3B). Immunohistochemistry (IHC) analysis in a set of prostate tissues of different grades and stages confirms that high grade and metastatic tumors express higher levels of MYC and EZH2 but lower IFNGR1 in these tumors (Fig. 3C). Thus, our finding suggests that *IFNGR1* downregulation by EZH2 may occur in a subset of metastatic prostate tumors associated with MYC.

[00219] **Example 4**

[00220] **EZH2-mediated inactivation of IFN- γ -JAK-STAT1 signaling pathway confers growth and survival advantages in MYC-dependent prostate cancer cells**

10 [00221] Activation of IFN- γ -STAT1 signaling is known to be tumor suppressive through the induction a number of IFN responsive genes, including the apoptosis-promoting *IRF1*. Loss of *IFNGR1* expression by EZH2 is expected to cause a reduced sensitivity to IFN- γ treatment, resulting in defective activation of JAK-STAT1 signaling and its downstream target genes. Consistent with this hypothesis, EZH2 knockdown in MYC-dependent DU145 and PC3 cells, but not in MYC-independent LNCaP and 22RV1 cells, resulted in robust activation of IFN genes in response to IFN- γ stimulation (Fig. 4A). Consistently, EZH2 knockdown in DU145 cells restored the IFNGR1 protein expression, enhanced the STAT1 phosphorylation and the expression of IFI16, a downstream target gene of STAT1 (Fig. 4B), as well as JAK2 phosphorylation in response to IFN- γ stimulation (Fig. 4C). Consistent with
15 MYC being upstream of EZH2, *MYC* knockdown in DU145 cells resulted in decreased EZH2 expression, which gave rise to a similar increase in *IFNGR1* expression and STAT1 activation in response to IFN- γ stimulation (Fig.4D).

[00222] Phenotypically, we found that, either *MYC* or *EZH2* knockdown, when combined with IFN- γ treatment, resulted in remarkable synergy in cell growth regression in MYC-dependent DU145 cells, indicating an induction of cell death (Fig. 4E, top). By contrast, no such an effect was seen in MYC-independent LNCaP cells (Fig. 4E, bottom). Further assessing cell death by sub-G1 DNA suggested an apoptosis induction following *EZH2* or *MYC* knockdown, in combination with IFN- γ treatment, in DU145 but not in LNCaP cells (Fig. 4F). Crucially, the enhanced apoptosis induced by the combination conditions were
20 IFNGR1-dependent, as the addition of a specific IFNGR1 neutralizing antibody CD119, which presumably blocks the binding of IFN- γ ligand to the IFNGR1, nearly completely abolished this apoptosis induction upon EZH2 or MYC knockdown (Fig. 4F).

[00223] As EZH2 has been linked to cancer stemness, the ability of EZH2 knockdown in tumorsphere formation in prostate cancer cells (prostatosphere), a growth feature associated with tumor initiating cells was further assessed. The cancer stem cell (CSC) hypothesis proposes that a population of tumor cells bearing stem cell properties is responsible for the origin and maintenance of tumors. Normal and cancer stem cells possess the ability to grow *in vitro* as self-renewing spheres, but the molecular basis of this phenotype remains largely unknown. A comprehensive culture system to grow prostatospheres (PSs) from both cancer cell lines and patient tumors has been established. Gene expression microarrays were then carried out to gain insight on the molecular pathways that sustain the PS tumor initiating cell (TIC) phenotype.

[00224] Prostatospheres are believed to be tumor-initiating cells that are responsible for tumor formation and prostatospheres appear in some examples to be resistant to chemotherapy. Hence, prostatospheres may contribute to chemo-resistance and disease progression/relapse post-treatment. Accordingly, it is an object of the invention to demonstrate the unexpected effect of the combination as described herein in the treatment of prostatospheres. In fact, the prostatospheres are highly sensitive to the combination as described herein and the use of said combination may represent an effective treatment strategy to completely eradicate the tumor cells including the tumor initiating cancer stem cells that show resistant to conventional chemotherapy.

[00225] As shown in Fig. 4G, EZH2 knockdown in combination with IFN- γ efficiently inhibited the tumorsphere formation in MYC-dependent DU145 and PC3 cells, but not in MYC-independent LNCaP and 22RV1 cells (Fig. 4G). Taken together, these findings support that MYC and EZH2 act concertedly in the same pathway to promote growth and survival advantages through inactivation of IFN- γ -STAT1 tumor suppressor pathway. Restoring the IFN- γ -STAT1 signaling following *EZH2* knockdown is able to sensitize the IFN- γ treatment in MYC-dependent prostate cancer cells.

[00226] **Example 5**

[00227] **Pharmacologic depletion of EZH2 by DZNep mimics EZH2 knockdown to restore *IFNGR1* expression and sensitize IFN- γ treatment**

[00228] The surprising and unexpected finding as described above lead the inventors to test pharmacologic approaches to restore IFN signaling. To this end, two exemplary types of

pharmacologic agents were exploited: one is the histone methylation inhibitor deazaneplanocin A (DZNep), which though not being specific is nevertheless able to effectively deplete EZH2/PRC2, leading to activation of EZH2 target genes; the second is recently reported catalytic inhibitors of EZH2 that can specifically inhibit H3K27me3 but do not affect EZH2. The results show that pharmacological depletion of EZH2 by DZNep in DU145 cells was able to mimic the *EZH2* knockdown and induced the expression of *IFNGR1*, which, when combined with IFN- γ , led to strong inductions of IFN genes (Fig. 5A), as well as STAT1 phosphorylation (Fig. 5B). Again, in agreement with the selective repression of *IFNGR1* by EZH2, DZNep treatment did not change *IFNARI* expression (Fig. 5A and 5B).

[00229] Like EZH2 knockdown, DZNep was able to induce a robust apoptosis when combined with increasing doses of IFN- γ in DU145 but not in LNCaP cells (Fig. 5C). Similarly, consistent with the MYC-dependency, such an induction of apoptosis was only seen in RWPE1-MYC cells, but not in RWPE1-PI3K or control RWPE cells (Fig. 10A). As a comparison, we also show that the other epigenetic compounds such as histone deacetylase inhibitors SAHA and TSA as well as DNA methylation inhibitor 5'Aza did not give rise to such a response (Fig. 10B), underscoring a unique ability of DZNep in this scenario. Again, the apoptosis induced by the drug combination was inhibited by the neutralizing antibody (CD119) of the IFN- γ receptor (Fig. 5D), which was accompanied by the abolished induction of STAT1 phosphorylation and PARP cleavage (Fig. 5E). We also show that Axon 1588, a small molecule inhibitor of JAK2, could similarly rescue DU145 cells from apoptosis (Fig. 10C). These findings, taken together, demonstrate that the apoptosis induced by the combination of DZNep and IFN- γ is largely mediated through the specific activation of IFN- γ -STAT1 signaling pathway.

[00230] Moreover, the co-treatment of DZNep and IFN- γ was also able to show a combinatorial effect in growth inhibition in MYC-dependent DU145 and PC3 cells but not in MYC-independent LNCaP and 22RV1 cells (Fig. 5F). Most strikingly, this combination nearly completely eliminated the formation of DU145 or PC3-derived prostatespheres but had no effect on LNCaP or 22RV1-derived prostatespheres (Fig. 5G). Consistently, we detected drastic increase in the expression of *IFN* genes in DU145 prostatespheres upon the combination treatment (Fig. 10D). These findings indicate that DZNep is able to recapitulate

the *EZH2* knockdown and synergize with IFN- γ to induce apoptosis, cell proliferation and tumorsphere inhibition in MYC-dependent prostate cancer cells.

[00231] **Example 6**

5 [00232] **Therapeutic effect of combined DZNep and IFN- γ treatment in vivo**

[00233] To confirm the above findings in vivo, we established the DU145 xenografts in athymic mice and treated them with vehicle, DZNep, IFN- γ , or both. Treatment with DZNep or IFN- γ alone slowed down the tumor growth, while the combination treatment resulted in a complete tumor growth arrest in average ($p < 0.01$) (Fig. 6A) and a few of these tumors showed tumor repression (data not shown). Throughout the study, both single or combination treatment were well tolerated in mice without overt signs of toxicity or weight loss $>10\%$, encouraging a potential future application of this treatment in the clinic (Fig. 6B). Immunohistochemistry (IHC) analyses of tumors resected from the mice confirmed the downregulation of *EZH2* and upregulation of *IFNGR1* within the tumors treated with DZNep or DZNep combined with IFN- γ (Fig. 6C). Thus, the combination of DZNep and IFN- γ is also effective in the xenograft tumor model and is able to induce the expected molecular changes within the tumors. Collectively, our data demonstrated a therapeutic approach that may provide benefit in advanced prostate cancers that undergo *EZH2*-mediated *IFNGR1* silencing.

20

[00234] **Example 7**

[00235] **Catalytic inhibitors of *EZH2* fail to recapitulate the *EZH2* knockdown effects**

[00236] Next, we wanted to test whether or not the catalytic *EZH2* inhibitors, which have been recently developed to selectively inhibit *EZH2*-mediated H3K27me3 and kill non-Hodgkin's lymphomas harboring *EZH2* activating mutations, are able to mimic the *EZH2* knockdown. As shown in Figure 7A, DU145 cells treated with such an *EZH2* inhibitor (GSK343) up to 2.5 μM for 3 days did not show an induction of *IFNGR1*, despite the efficient depletion of H3K27me3 at as low as 0.1 μM . Cells treated with another *EZH2* inhibitor, GSK126, in higher doses (up to 10 μM) for 10 days only showed a modest induction of *IFNGR1* (Fig. 7A and 7B). In contrast, DZNep, which depleted *EZH2*, as well as the other two PRC2 proteins *EED* and *SUZ12*, induced a marked expression of *IFNGR1*, albeit at a much lower efficiency in depleting H3K27me3 (Fig. 7A and 7B). At the *IFNGR1*

30

gene promoter level, we saw that DZNep treatment reduced both EZH2 and H3K27me3 enrichments, though GSK126 was more efficiently depleted H3K27me3 (Fig. 7C). Accordingly, unlike the DZNep/IFN- γ treatment, we failed to see an apoptotic effect of GSK343/GSK126 in combination with IFN- γ in DU145 cells, treated for either 3 days or 10 days (Fig. 7D). Moreover, GSK126/ IFN- γ combination also had no effect on DU145 tumorsphere formation (Fig. 7E). Taken together, these findings suggest that although H3K27me3 is a repressive hallmark associated with PRC2 activity, simply inhibiting H3K27me3, without affecting PRC2, is insufficient to induce a robust *IFNGR1* expression and thus unable to mimic *EZH2* knockdown. Thus, additional mechanisms might be required to coordinate with H3K27me3 to implement PRC2-mediated *IFNGR1* silencing in the absence of gain of function *EZH2* mutations in epithelial tumors. This result is consistent with a very recent report showing that a peptide blocking EZH2-EED binding, which leads to EZH2 downregulation, is able to induce the loss of cell viability in solid tumor cells, while GSK126 is unable to do so though it has a much greater potency in inhibiting H3K27me3.

15

[00237] **Example 8**

[00238] **EZH2-mediated *IFNGR1* repression occurs widely in human cancers**

[00239] Apart from advanced prostate cancer, Oncomine analysis also shows that the upregulation of EZH2 accompanied by the down regulation of IFNGR1 is commonly observed in many other cancer types (Fig. 11A). In particular, the reverse correlation of *EZH2* with *IFNGR1* is also clearly shown in MYC-driven Burkitt's lymphoma vs. other types of lymphomas (Fig. 11B and C), indicating that EZH2-mediated *IFNGR1* expression may also occur in other MYC-driven cancers.

[00240] As we have previously shown that EZH2 epigenetic gene silencing activity is more prevalent in ER positive breast cancer cells, we sought to further validate the EZH2-mediated *IFNGR1* repression in breast cancer. Data extracted from Gene expression-based Outcome for Breast cancer Online (GOBO) (<http://co.bmc.lu.se/gobo>) shows the downregulation of *IFNGR1* in luminal subtype of breast cancer in both cell lines and clinical samples (Fig. 12A and B). Using both western blotting and immunohistochemistry (IHC) analyzes we confirmed the downregulation of IFNGR1 protein in both ER + luminal breast cancer cell lines (Fig. 12C) and ER + primary tumor specimen relative to the ER- counterparts (Fig. 12D).

30

[00241] *IFNGR1* downregulation in ER+ tumors seems to be clinically significant as it is associated with a poorer distant metastasis free survival (DMFS) in ER+ tumors but not in ER- tumors (Fig. 11E). As expected, EZH2 knockdown or DZNep treatment in ER+ luminal MCF7 cells led to an induction of *IFNGR1* at both mRNA and protein levels but this was not
5 seen in ER- basal like MDA-MB-231 cells (MB231) (Fig. 11F). ChIP analysis showed the enrichments of EZH2 and H3K27me3 in the *IFNGR1* promoter in MCF7 but not MB-231 cells (Fig. 11G). Finally, combination of DZNep and IFN- γ resulted in robust apoptosis in luminal MCF-7 and T47D cells, but not in basal-like cell lines (Fig. 11H). Consistently, in
10 both MCF-7 and T47D cells, we see that DZNep treatment restored the *IFNGR1* expression, increased STAT1 activation and PARP cleavage when co-treated with IFN- γ (Fig. 11I). Thus, EZH2 represses *IFNGR1* expression in ER+ luminal breast cancer cells to render susceptibility to the combined treatment with DZNep and IFN- γ .

[00242] Immunohistochemistry (IHC) was used to validate the Oncomine observation in liver and lung and cancers. In liver cancer, EZH2 upregulation and IFNGR1 downregulation
15 occur mainly in high-grade tumors (Fig. 13A and B). In a series of liver cell lines showing various levels of IFNGR1 expression, DZNep/IFN- γ combination induced strong apoptosis in cell lines with lower level of IFNGR1 but not in the cell line with high IFNGR1 (Fig. 13C). In lung cancer, EZH2 upregulation and IFNGR1 downregulation occur mainly in SCLC and metastatic lung cancer as well as a subset of NSCLC (Fig. 13A and B). Again, DZNep/IFN- γ
20 treatment was more effective in NSCLC lines showing the higher EZH2 and lower IFNGR1 (Fig. 14D and F). Taken together, these findings suggest that EZH2-mediated *IFNGR1* repression occurs in subsets of multiple human cancers and the expression levels of EZH2 and IFNGR1 might be used as a biomarker strategy to identify the cancer patients that may potentially benefit from EZH2 and IFN- γ -based therapies.

25 The inventors interestingly identified a common EZH2 target that may be of therapeutic importance in many cancers. By analyzing the MYC-mediated transcriptional alteration in prostate cancer cells, a defective IFN-JAK-STAT1 signaling pathway inactivated by EZH2 in a MYC-dependent manner was uncovered. In one example, it is shown that the direct silencing of *IFNGR1* by EZH2 mediates the inactivation of this pathway, rendering the
30 cancer cells insensitive to IFN γ treatment. As such, restoration of *IFNGR1* expression by EZH2 inhibition, either through gene knockdown or pharmacologic depletion, sensitizes the ability of interferon γ to activate the downstream STAT1 tumor suppressor pathway, leading

to robust apoptosis. In the present disclosure, the inventors show for the first time that this molecular mechanism is MYC-dependent, which is consistent with MYC being an upstream regulator of EZH2

5 [00243] **Cell culture and treatments**

[00244] Epithelial cell lines were obtained from the American Type Culture Collection and cultured them according to the recommended protocols. MB231, BT549, MCF7, T47D, BT474, MB361, MB415, MB436, Hs578T, MB157, PC3, DU145 cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). VCap cells were grown in the addition of 1% sodium pyruvate and 1% sodium bicarbonate. SKBR3 cells were maintained in McCoy's 5A medium. HCC1806, HCC1937, 22RV1, and LNCaP were maintained in RPMI medium supplemented with 10% FBS.

[00245] HMEC and MCF10A normal breast epithelial cell line was grown in DMEM/F12 supplemented with 5% horse serum, 20ng/ml EGF, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10µg/ml insulin, and penicillin/streptoMYCin (Invitrogen). RWPE1 and all its derivative sub-lines were grown in K-SFM with 50mg/ml BPE, 5ng/ml EGF (Invitrogen). All media were supplemented with 5000U/mL penicillin/streptomycin (Invitrogen).

[00246] All cells were maintained at 37 °C with 5% CO₂. Cells were grown until they were 80% confluent before they are treated the respective drugs. For drug treatment, DZNep and GSK126 were purchased from Pharmaron Inc. (Beijing, China), GSK343 was kindly provided by Chemical Probes of University of Toronto, 5'Aza, TSA and human recombinant IFN-γ was purchased from Sigma. For rescue experiment using IFNGR1 blocking antibody, the neutralizing antibody that specifically targets IFNGR1 (anti-CD119, GIR-208, BD Pharmingen) was added to the medium 4 hour prior to the addition of DZNep or/and IFN-γ.

25

[00247] **Small interfering RNA and plasmids**

[00248] siRNA transfections were conducted using Lipofectamine RNAiMax (Invitrogen). To generate stable over-expression cell lines, target genes from their respective transient expression plasmids were subcloned into the PMN retroviral expression vector. pBabe puro HA-PIK3CA (E545K) was purchased from Addgene and the coding region was subcloned into pMN GFP/IRES retroviral vector (a gift from Dr Linda Penn's lab). PMN-MYC plasmid was from the courtesy of Dr. Linda Penn. RWPE1 cells were infected with retrovirus

30

packaged with PMN-MYC or PMN-PI3KCA (E545K) or the PMN empty vector for 48 hours and followed by GPF sorting.

[00249] Target-specific siRNA and non-targeting control siRNA were purchased from 1st Base Singapore and Integrated DNA technologies (IDT) with the following target sequences respectively: EZH2 siRNA: 5'-GACUCUGAAUGCAGUUGCU-3' (SEQ ID NO: 1); MYC siRNA: 5'-UCCUGAGACAGAUCAACAACCG-3' (SEQ ID NO:2). All siRNA were designed by 1st Base Singapore and IDT respectively. For transfection, 30 nM siRNAs were used to transfect cells. 48 h after transfection cell pellets were collected and subjected indicated assays.

[00250] **Microarray gene expression analysis and Quantitative-PCR**

[00251] Total RNA was isolated by using Trizol (Invitrogen) and purified with the RNeasy Mini Kit (Qiagen). The microarray hybridization was performed using the Illumina Gene Expression Sentrix BeadChip HumanRef-8_V3, and data analysis was performed by GeneSpring software from Agilent Technologies as described previously. The analyzed gene sets by GeneSpring were next subjected to Ingenuity Pathway Analysis (IPA) for gene ontology (GO) analysis. Reverse transcription and quantitative PCR assays were performed using High Capacity cDNA Archive kit and KAPA SyBr Fast qPCR kit (KAPA biosystems). For quantification of mRNA levels, 18S level was used as an internal control. All reactions were analyzed in an Applied Biosystems PRISM 7500 Fast Real-Time PCR system in 96-well plate format. The sequences of all primers are listed in Table 3.

Table 3: Sequences of primers used in microarray and qPCR.

Gene	Forward Primer 5'-3'	SEQ ID NO:	Reverse Primer 5'-3'	SEQ ID NO:
Stat1	GCCTGGAAGATTTACAAG ATGAATATG	3	TTGGTCTCGTGTCTCTGT TCTG	4
Stat2	ATGAGTGTGGCCGTTGCA	5	TGGGAAAAGGGCTGAATG TC	6
Stat3	TGTTCTCTATCAGCACAAT CTACGAA	7	CAATCCGGGCAATCTCCA T	8
IRF1	CATGGCTGGGACATCAAC AA	9	TTGTATCGGCCTGTGTGA ATG	10

TAP1	GGGCCTTGTCAGTTCCA	11	GGTGAATGTCAGCCCCTG	12
	A		TAG	
IFITM1	GGCTTCATAGCATTGCGCT	13	TCACGTCGCCAACCATCTT	14
	ACT			
PSMB8	GGAGGCGTTGTCAATATG	15	GTGCAGCAGGTCCTGAC	16
	TACCA		ATCT	
IRF9	CCCGACCTCACCGATGAC	17	TCTCGCGAAGCTGGATGT	18
			C	
OAS1	AGCACTGGTACCAAAATT	19	CCTCGCTCCCAAGCATAG	20
	GTAAGAAG		AC	
MX1	GACAGGACCATCGGAATC	21	ACGTCCACAACCTTGTCTT	22
	TTG		CAGT	
XAF1	GATGTGTCAGCAGAGCAT	23	TGGCACTCATTGGCCTTAT	24
	GCA		G	
IFI16	ACTGAGTACAACAAAGCC	25	TTGTGACATTGTCCTGTCC	26
	ATTTGA		CCAC	
IFNGR1	GTGTGAGCAGGGCTGAGA	27	TCCAATATACGATAGGG	28
	T		TTCA	
IFNAR1	ATGGGTGTTGTCCGCAG	29	CTCCTGTTCCACCTCAGGA	30
			T	
EZH2	AGTGTGACCCTGACCTCT	31	AGATGGTGCCAGCAATAG	32
	GT		AT	
18S	CGAACGTCTGCCCTATCA	33	ACCCGTGGTCACCATGGT	34
	ACTT		A	

[00252] **GEO Accession**

[00253] Microarray data reported herein from the comparison against RWPE1-vector, RWPE1-MYC and RWPE1-PI3K transformed cells (Figure 1A) have been deposited in Gene Expression Omnibus with the accession code GSE43686.

[00254] **Dual Luciferase Reporter Assay**

[00255] STAT1-specific reporter plasmid pSTAT1, its negative control pGL4 empty vector, and pRL-null were purchased from Signosis. During transfection, 500ng pGL4/pSTAT1 and 20ng pRL-null were diluted in 50µl OPTI-MEM. After 5 minutes of incubation, 2.6µl of FugeneHD was added and further incubated for 20 minutes. The

transfection mixtures were then added into 400 μ l of complete medium-containing 24-well plate, which was seeded with monolayer RWPE cells 18 hours prior transfection. The media of the transfected cells was changed with fresh complete media 24 hours post transfection. Cells were harvested 48 hours post transfection and luciferase activity was detected using the
5 Dual Luciferase system (Promega) following manufacturer's protocol. To analyze luciferase activity, Firefly signals of pGL4/pSTAT1 were normalized to Renilla signals of pRL-null in respective samples. pSTAT1/pRL-null ratio were further normalized to pGL4/pRL-null ratio to obtain normalized values corrected for the changes of basic transcription activity for indicated treatment of the cells.

10

[00256] **pJAK2 and total JAK2 ELISA assay**

[00257] pJAK2 levels were assessed using an ELISA assay kit (Tyr1007/1008, Life Technologies) and total JAK2 level with JAK2 (total) ELISA assay kit. Cells were first lysed with RIPA buffer and processed in the same way as western blot samples. pJAK2 and total
15 JAK2 levels were determined by performing the ELISA assay on the processed cell lysates according to the manufacturer's protocol. The results were expressed as fold change after normalizing the pJAK2 (Tyr1007/1008) level to the total JAK2 level.

[00258] **Western Blotting**

20 [00259] Western Blotting was performed as described previously. Briefly, Cells were scraped, collected, and lysed in RIPA buffer. To release histones from chromatin, cell lysates were further sonicated for 15 sec using a XL2000 Microson Ultrasonic Processor (Misonix). Equal amounts of protein (30 μ g) were separated on SDS-polyacrylamide gels and transferred to PVDF membranes. The blots were probed with antibodies against EED (07-
25 368), SUZ12 (07-379), trimethylated H3-K27 (07-449), Acetyl-Histone H3 (06-599), which were purchased from Upstate Biotechnology. IFNGR1 (GIR-94) and anti-IFI16 (1G7) were purchased from Santa Cruz. EZH2 phospho S21 (00388) was purchased from Bethyl Laboratories. EZH2 (AC22), P110 α PI3K, p-AKT (T308), p-AKT (S473), pSTAT1Y701, total STAT1, Histone H3 (3H1), Beclin-1 and cleaved PARP were purchased from Cell
30 Signaling. Myc and Actin were purchased from Roche Applied Science and Sigma-Aldrich, respectively.

[00260] Chromatin Immunoprecipitation (ChIP) Assay

[00261] ChIP assays were performed as described previously. Briefly, pre-cleared chromatin from the cells was immuno-precipitated with antibodies against EZH2 (Active Motif), H3K27me3 (Millipore) or rabbit IgG (Santa Cruz Biotechnology) as a control.

- 5 The immunoprecipitated DNA was quantified by quantitative real-time PCR using KAPA SyBr Fast qPCR kit (KAPA biosystems) with the specific ChIP primers as listed in the Table 4. Quantification of binding to the promoter was defined as the percentage of the whole cell lysate input DNA. The fold enrichment was derived by normalizing the specific antibody enriched against the IgG-enriched chromatin. CNR1 serves a positive control and Actin is a
- 10 negative control. Significance of target genes was assessed relative to Actin level.

Table 4: Sequences of specific ChIP primers used

Gene	Primer ID	Forward Primer 5'-3'	SEQ ID NO:	Reverse Primer 5'- 3'	SEQ ID NO:
IFNAR1		TTCGTTTGGAAAGAGG GTGTTG	35	ACGCAAAAGGGGAAG TTAGTTAAGC	36
CNR1		GCAGAGCTCTCCGTA GTCAG	37	AACAGGCTGGGGCC ATACAG	38
ACTIN		AGTGTGGTCTGCGA CTTCTAAG	39	CCTGGGCTTGAGAGG TAGAGTGT	40
IFNGR1	P1	TGGTGGGTGCTGTGA TTGTG	41	AACCCAGTCTTCTGT TCCTGAGA	42
	P2	CTTCCTCCGCTCTGC TTCCT	43	GATTAGGGAGTGCTC TTGGAATAAA	44
	P3	TCAAGACCCAACCTG AATTAGAACT	45	TTAGCTCAGTACTTC TCAAACCTCAACA	46
	P4	CGCTGAAGGACTTAG CAATGTG	47	GGGTTTGTCTGTTAT TTTGCATCTC	48
	P5	CCCCAGGAAACCGA AAAAA	49	CAACCTGGCACCCCA TTC	50
	P6	GCAGCATGGCTCTCC TCTTT	51	CGCGGTGCCCATCTC A	52
	P7	CGTCTTCTTACTGTA	53	TGCAGGCAACCGTA	54

		CCTTTTTTTTATGG		GCATAC	
	P8	GGATTGCCGGCACTC ACTA	55	CGAAGAACAAACCC GTACGAA	56
STAT1	ChIP 0	CTCGAGGATCCGATC ATTTTAAA	57	GGCAGGCAAAGAGC TTGTG	58
	ChIP 0.5	GGTGCCGTGGCATCT CTT	59	GCACATCTATTTGTT CTTCTTGTCACA	60
	ChIP 1	CCAGCGAAGAGTTG GGTGAA	61	GGGACTTCTCACCCCT GAGTTTG	62
	ChIP 1.5	TTGTATGGAGAATGG ATTTAAAAGGTAGA	63	CTGCAGTAGATTCCC GAATGG	64
	ChIP 2	GGAGAGGTGTGGAC GGGATA	65	TCACCCACAGCTTCA GTTTCC	66
	ChIP 3	CTGGATTCTCGGCGA TGAA	67	TGTGFTTGCAGAAGC CCAAA	68
	ChIP 4	GCCACCTGTTCTCGG AGATG	69	AGAGCACGACTGGC AAGGA	70
MX1	ChIP-2	GGTTGCCAGCCCTA GGA	71	CAGCTCCCTGTGCTG AAATCT	72
	ChIP-1.5	CCCGTGACAATTCTG AGGAAA	73	CCCTAGTCCAGCTTG GAGGAT	74
	ChIP-1	TCCTTCCACACACCC GTTTC	75	TCCCTGGAGTCTGGC TCATC	76
	ChIP-0.5	ATACGTGCAGGCTTG GATGAC	77	AGGCCCGTCTGAGG ATCAA	78
	ChIP+0.5	GATGCTAACCGCGCC TCTAC	79	AGCCATTTTAGGAGC CCTTG	80
IRF1	ChIP-2	TTTTTATAGTGCCT GTTGCCTTCA	81	GAAGTTTGCATCTTT GTGGTCTGA	82
	ChIP-1.5	GGTCACAGCACTCAG ATTGCA	83	CCCTCCCGTAGAGGA AATGC	84
	ChIP-1	CAGCCGTCTGGGCTT CTC	85	CCCCTGGCTGGCTTT AGG	86
	ChIP-0.5	CCCTTCGCCGCTAGC	87	TGCGTGCCGTCATTT	88

		TCTA		CG	
	ChIP-0	AAGGGTTAGCGTCCT GGTCTTAG	89	CCATTCTACGCCTTC CTGAC	90
OAS1	ChIP-2	CCACAAAAGAAAGA TAGCTGGAAAA	91	TCTTCCTTGCCCCAT GTGTT	92
	ChIP-1.5	TCACATTCATACCCA CTTTTAAATACG	93	CCAGTTACCACCCTT CTTCTAGAAA	94
	ChIP-1	AAAAATGAGCTGGG TGCAGTAAC	95	GCCCCAGCCTCCTGA ATAC	96
	ChIP-0.5	AGAGGCAATTTTGTA GTGTTAGAATCAT	97	CACTGCAAAAAGAA AAAAAGTCAGAA	98
	ChIP+0.5	GCACCTGCTGGCTGC AA	99	TGAGGAAATTGGAA CACAGAGTAGTT	100

[00262] **Immunohistochemistry-Tissue microarray (IHC-TMA)**

[00263] Tissue microarray slides (PR956, BR1503b, LC2083, and LV6161) were purchased from US Biomax. Staining and image analysis of tissue microarray were performed by Histopathology Department from Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), Singapore. Anti-EZH2 (D2C9 XP) antibody was purchased from Cell Signaling, anti-MYC (9E10) and anti-IFNGR1 antibody (GIR-94) was purchased from Santa Cruz Biotechnology. Briefly, five-micron paraffin-embedded tissue sections cut, deparaffinized, rehydrated, antigens were retrieved by Proteinase K solution; sections were then incubated in 3% H₂O₂ at room temperature to block endogenous peroxidase. Slides were incubated in primary antibody against EZH2 or IFNGR1 for 45 mins followed by 30 min incubation with anti-mouse Labelled Polymer (Dako, CA). Specificity of the immunostaining was determined by the inclusion of isotype-specific IgG as negative control. The detection system was DAB+ Substrate-Chromogen Solution (Dako). The sections were counterstained with hematoxyalin.

[00264] Slides were scanned at 20x using an Leica SCN400 slide scanner (Leica Microsystems, Germany). Images were exported to Slidepath Digital Image Hub (Leica Microsystems, Germany) for viewing. Tissue micro-array cores were analyzed using the Measure Stained Cells algorithm of Slidepath Tissue IA software (Leica Microsystems,

Germany). Data was collated using Microsoft Excel. Scanning and image analysis was performed by the Advanced Molecular Pathology Laboratory, IMCB, Singapore.

[00265] **Cell Viability assay**

5 [00266] The optimal cell seeding was determined empirically for all cell lines by examining the growth of a wide range of seeding densities in a 96-well format to identify conditions that permitted proliferation for 6 days. Cells were then plated at the optimal seeding density 24 h before siRNA or drug treatment in triplicate. Plates were incubated for 6 days at 37°C in 5% CO₂. Cells were then lysed with CellTiter-Glo (CTG) (Promega) and
10 chemiluminescent signal was detected with a microplate reader (TECAN). In addition, an untreated plate of cells was harvested at the time of drug or siRNA addition (T₀) to quantify the starting number of cells. CTG values obtained after the 6 day treatment were expressed as percentages of the T₀ value and plotted against time of treatment. Cells received 1-5µM of DZNep, 25ng/mL of IFN-γ and 0.1-2.5µM of GSK343 unless stated otherwise for 72-96 h.

15

[00267] **FACS analysis**

[00268] For the assessment of cell death, cells were harvested in 70% ethanol. Fixed cells were stained with Propidium Iodide (P.I) (50µg/mL). The stained cells were analyzed for DNA content by FACS in a FACSCalibur (Becton Dickinson Instrument). % of cell death
20 was defined as the sub-G1 population quantified using the CellQuest software (Becton Dickinson). The percentage of dead cells or sub-G1 cells was calculated by comparing the results of each experiment to the results from DMSO-treated cells. Each assay was repeated a minimum of three times, with results reported as means + s.e.m.

25 [00269] **Prostatosphere formation assay**

[00270] Prostatospheres were generated according to protocols known to the skilled person in the art. In order to obtain prostatospheres from either DU145 or LNCaP, exponentially growing cultures were dissociated to single cells by standard trypsinization, washed three times with PBS and plated at a density of 1x10⁴ cells/well in 6-well ultra-low attachment
30 plates (Corning) containing 3ml of SCM medium (DMEM:F12 plus 10 ng/mL bFGF, 20 ng/mL EGF, 5 mg/mL insulin, and 0.4% BSA) supplemented with 1% KO serum replacement (Invitrogen/Gibco). The cells were treated with DZNep or IFN-γ as indicated the next day and cultured for 7 days. 7 days old prostatospheres formed were stained with 4

µg/ml p-Iodonitrotetrazolium Violet (INT) overnight and were counted and analyzed using a GelCount™ automatic plate scanner (Oxford Optronics) and GelCount Version 0.025.1 software (Oxford Optronics). Plates were scanned at 1200 dpi and the colony detection algorithm was optimized for each cell type and culture time.

5

[00271] **Mouse Experiments**

[00272] For *in vivo* evaluation of DZNep and IFN-γ treatment, the experiments were conducted in compliance with animal protocol approved by the ASTAR-Biopolis Institutional Animal Care and Use Committee (IACUC) of Singapore. DU145 cells were subcutaneously
10 injected into 6-8 week male nude mice at 5×10^6 cells, followed by treatment with vehicle, IFN-γ (1×10^7 IU/kg) alone, DZNep (1mg/kg) alone or combined DZNep (1mg/kg) with IFN-γ (1×10^7 IU/kg). IFN-γ was administered by intraperitoneal injection daily and DZNep by subcutaneous injection on every alternating day over a duration of 38 days after average tumor size reached around 150mm^3 . Tumors were measured by vernier calliper at least twice
15 per week and tumors volume was calculated with formula: $V = W \times W \times L / 2$. Each xenograft treatment arm comprised of 5–8 mice. Differences among groups and treatments were determined by ANOVA followed by *t* tests. (***) $p < 0.001$, n.s.=not significant) Error bars represent means \pm s.e.m

20 [00273] **Statistical analyses**

[00274] All *in vitro* experiments were repeated at least three times unless stated otherwise, and data are reported as means + s.e.m. Differences among groups and treatments were determined by Student's *t* test and $p \leq 0.05$ was considered significant unless stated otherwise. Statistical test and graph construction was performed using Graphpad Prism
25 software; version 5.

[00275] **Methylation Specific PCR**

[00276] Bisulfite modification of DNA was carried out by using the EZ DNA methylation-Gold kit (ZYMO Research) according the manufacturer's protocol. The CpG island DNA
30 methylation status was determined by methylation specific PCR (MSP) as described in the art. MSP primers targeting the IFNGR1 promoter for methylated sets includes: Forward primer M, 5'-GTGTTTATTGTTGGGTGTTGC-3' (SEQ ID NO: 101) and Reverse Primer M, 5'-GTCACCGAAATCTATACCGAC-3' (SEQ ID NO: 102). For unmethylated sets includes:

Forward Primer U, 5'-TGTTTATTGTTGGGTGTTGTGT-3' (SEQ ID NO: 103) and Reverse Primer U, 5'-TTCCATCACCAAAAATCTATACCAA-3' (SEQ ID NO: 104).

[00277] **Anchorage-independent colony formation assay**

5. [00278] To assess anchorage-independent growth of RWPE1 transformed cells, 1×10^4 cells were suspended in K-SFM containing 0.3 % agar, 10 % fetal bovine serum, and layered on K-SFM containing 0.6% agar and 10% FBS in 6-well plate. After 3 weeks, colonies were stained 18-24 hours with iodinitrotetrazolium chloride (Sigma). Colonies from three replicate wells were quantified using GelCount colony counter (Oxford Optronix).

Claims

1. A pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity.
2. The pharmaceutical composition of claim 1, wherein the interferon-gamma receptor is interferon-gamma receptor 1 (IFNGR1) encoding for interferon-gamma receptor (IFNGR1) subunit 1.
3. The pharmaceutical composition according to claim 1 or claim 2, further comprising one or more pharmaceutically acceptable excipients, vehicles or carriers.
4. The pharmaceutical composition according any one of the preceding claims, wherein said inhibitor is selected from a group consisting of:
 - (-)-1-[(1R,4R,5S)-3-(Hydroxymethyl)-4,5-dihydroxy-2-cyclopenten-1-yl]4-aminoimidazo[4,5-c]pyridine hydrochloride (DZNep; 3-deazaneplanocin A);
 - 1-{[4-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-2-yl]sulfanyl}-3,3-dimethylbutan-2-one;
 - 4-[4-(4-methyl-1,3-thiazol-2-yl)phenyl]-1,2,3-thiadiazole;
 - 2-[(3,4-dichlorophenyl)carbamoyl]amino} benzoic acid;
 - N-(2-methylquinolin-6-yl)quinoxaline-2-carboxamide;
 - 2-[(4-tert-butylphenyl)carbonyl]-1H-imidazole;
 - 1-(2-hydroxyphenyl)-3-[4-(methoxymethoxy)phenyl]propane-1,3-dione;
 - N-(3-acetylphenyl)-8-methoxy-2-oxo-2H-chromene-3-carboxamide;
 - 1-{3-[4-(2-phenylethynyl)phenyl]-1H-pyrazol-1-yl} ethan-1-one;
 - 3-(thiophen-2-yl)benzoic acid;
 - 5-(6-methoxynaphthalen-2-yl)-1H-pyrazole;
 - 4-methyl-5-[3-(methylsulfanyl)-1H-pyrazol-5-yl]-2-(thiophen-2-yl)-1,3-thiazole;
 - 2-[(2-chloro-6-fluorophenyl)methyl]sulfanyl}-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethan-1-one;
 - 3-(3-chlorophenyl)-5-(thiophen-3-yl)-1,2,4-oxadiazole;

- 2,3-dihydro-1-benzofuran-5-ylmethanimidamido thiophene-2-carboxylate;
N-(2,3-dihydro-1,4-benzodioxin-6-yl)[(furan-2-ylmethyl)carbamoithieryl]formamide;
N-[4-(diethylamino)phenyl]-3-methylbenzamide;
3-[5-(1,2-oxazol-3-yl)thiophen-2-yl]-5-phenyl-1,2,4-oxadiazole;
5 ethyl(2E)-2-cyano-3-[(E)-{[4-dimethylamino)phenyl]methylidene}amino](methane)
sulfonimidamido}prop-2-enoate;
(2Z)-2-(4-ethylphenyl)-3-(4-methoxyphenyl)prop-2-enenitrile;
5-tert-butyl-3-methyl-N-phenylthieno[3,2-b]thiophene-2-carboxamide;
5-(1-butyl-2-oxo-2,3-dihydro-1H-indol-3-ylidene)-2-(piperidin-1-yl)-4,5-dihydro-1,3-
10 thiazol-4-one;
(2E,6E)-2,6-bis(thiophen-2-ylmethylidene)cyclohexan-1-one;
2-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-benzothiazole;
2-chloro-N-[3-hydroxy-4-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-5-nitrobenzamide;
6-chloro-2-phenyl-4H-thiochromen-4-one methyl 2-(3,4-dihydro-2H-1,5-
15 benzodioxepine-7-amido)benzoate;
3-chloro-N,N-dimethyl-4-[(1E)-[2-(quinoxalin-2-yl)hydrazin-1-
ylidene]methyl]aniline;
(2E)-1-(2-methyl-1H-indol-3-yl)-3-(thiophen-2-yl)prop-2-en-1-one;
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(thiophen-2-yl)-1,3-thiazole-4-carboxamide;
20 4-[(E)-2-(1-methyl-1H-1,3-benzodiazol-2-yl)ethenyl]-1,3-thiazole;
3-(4-bromophenyl)-3,4-dihydro-1,2,3-benzotriazin-4-one;
N-(2,4-dichlorophenyl)-3,4-dihydro-2H-1-benzopyran-2-carboxamide;
N,N-dimethyl-4-[(E)-2-phenylethenyl]aniline;
2-(3,4-dichlorophenyl)quinoxaline;
25 N-(3-tert-butyl-1H-pyrazol-5-yl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide;
(2E)-2-(1,3-benzothiazol-2-yl)-3-(4-chlorophenyl)prop-2-enenitrile;
(4-tert-butylphenyl)methanimidamido 2-(thiophen-2-yl)acetate;
5-[4-(3-methyl-1-benzothiophen-2-yl)-1,3-thiazol-2-yl]-1,2-oxazole;
1-(4-fluorophenyl)-3-(1-phenyl-5-propyl-1H-pyrazol-4-yl)urea;
30 2-[(2Z)-2-phenyl-2-[(2E)-2-(thiophen-2-ylmethylidene)hydrazin-1-ylidene]ethyl]-1H-
1,3-benzodiazole;

- N-{7-oxo-8-oxa-4-thiatricyclo[7.4.0.0^{2,6}]trideca-1(9),2,5,10,12-pentaen-5-yl} thiophene-2-carboxamide;
- 2-(2-chlorophenyl)-1-[4-(dimethylamino)phenyl]ethan-1-one ethyl 4-cyano-1-(4-methylphenyl)-1H-pyrazole-3-carboxylate;
- 5 3-hydrazinylquinoxaline-2-thiol;
- 1-[(5-tert-butylthiophen-2-yl)carbonyl]piperidine;
- 3-[5-(2-phenylethynyl)thiophen-2-yl]-1-(thiophen-2-ylcarbonyl)-1H-pyrazole;
- 2,5-dichloro-N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)thiophene-3-carboxamide;
- 1-tert-butyl-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazole-3-
- 10 carboxamide;
- 4-(5-propylpyridin-2-yl)benzotrile;
- 5-(4-chlorophenyl)-3-(2,2-dichloroacetamido)thiophene-2-carboxamide;
- (4-methanesulfonamidophenyl)methanimidamido thiophene-2-carboxylate;
- ethyl 7-methyl-2-phenylpyrazolo[1,5-a]pyrimidine-6-carboxylate;
- 15 6-(4-chlorophenyl)-3-phenylthieno[2,3-e][1,2,4]triazine;
- 1-{1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl}-2,3-dihydro-1H-indole;
- 5-(4-chlorophenyl)-2-(4-methylphenyl)-2H-1,2,3,4-tetrazole;
- 4-[(1 E)-[2-(3,5-dichloropyridin-4-yl)hydrazin-1-ylidene]methyl]-N,N-
- dimethylaniline;
- 20 3-(5-tert-butyl-1,2-oxazol-3-yl)-1-phenylurea;
- (4-chlorophenyl)methanimidamido 3-chlorothiophene-2-carboxylate;
- N-{4-[(E)-2-phenyldiazen-1-yl]phenyl} acetamide;
- methyl 4-[(pyrimidin-2-ylsulfanyl)methyl]benzoate;
- 2-phenylimidazo[1,2-a]pyridine;
- 25 6-chloro-2-phenyl-4H-thiochromen-4-one;
- 2-[[4-methylphenyl)methyl]sulfanyl]-5-(pyrazin-2-yl)-1,3,4-thiadiazole;
- 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one;
- (E)-[I-(1H-pyrrol-2-yl)ethylidene]amino N-(4-chlorophenyl)carbamate;
- 1-benzoyl-3-2,3-dihydro-1H-inden-5-ylthiourea;
- 30 1-{1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl}-2,3-dihydro-1H-indole;
- N,5-diphenyl-1,3,4-oxadiazole-2-carboxamide;
- (3Z)-3-(2,3-dihydro-1-benzofuran-5-ylmethylidene)-2,3-dihydro-1H-indol-2-one;

- [(3-methylbutyl)sulfanyl]-N-phenylformamide;
2,4-dihydroxy-5,7-diphenylpyrano[2,3-d]pyrimidin-8-ium perchlorate;
ethyl 7-hydroxy-9-oxo-9H-xanthene-2-carboxylate;
5 [({[3,5-Dimethyl-1-(2-methyl-2-propanyl)-1H-pyrazol-4-yl]methylene} amino)oxy]{{[3-(trifluoromethyl)phenyl]amino}methanone};
5-[4-iodophenyl]amino]-3-phenyl-1,3-thiazolidine-2,4-dione;
N-(furan-2-ylmethyl)-2-[methane(4-phenoxyphenyl)sulfonamido]acetamide
N-(3-methoxyphenyl)-6-phenylpyridazin-3-amine;
ethyl (2E)-3-[(2-chlorophenyl)amino]-2-cyanoprop-2-enoate;
10 1-[3-chloro-1-benzothiophen-2-yl]carbonyl]-1H,2H,3H,4H,6H,10bH-pyrimido[2,1-a]isoindol-6-one;
2-(4-chlorophenyl)-5-[(cyclopropylmethyl)sulfanyl]-1,3,4-oxadiazole;
1-[6-(benzyloxy)-3-tert-butyl-2-hydroxyphenyl]ethan-1-one;
3-[(1 E)-1-[(2,2-dichloroethenyl)imino]-2,2-dimethylpropyl]-1-(4-
15 methylphenyl)thiourea;
6,7-dimethyl-2-phenylquinoxaline;
5-(2,3-dihydro-1-benzofuran-5-yl)-3-(4-fluorophenyl)-1,2,4-oxadiazole;
2-{4-[(4-methylphenyl)methoxy]phenyl}acetonitrile;
1-cyclohexyl-3-8-oxatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-5-
20 ylurea;
5-(1,2,3-thiadiazol-4-yl)-3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole;
N-(2-methylquinolin-6-yl)-2-phenylacetamide;
3-(piperidin-1-ylcarbonyl)-5-(thiophen-2-yl)-1,2-oxazole;
N-(3,4-dimethylphenyl)[(E)-N'-(thiophen-2-
25 ylmethylidene)hydrazinecarbonyl]formamide;
2-(2,3-dimethoxyphenyl)-2,3-dihydro-1,3-benzothiazole;
2-methyl-5-(naphthalen-2-yl)-1,3-thiazole hydrobromide;
(cyclohexylcarbamoithiyl)-N-(4-fluorophenyl)formamide;
4-(1,3-benzothiazol-2-yl)-1-methyl-1H-pyrazol-3-amine;
30 (4-tert-butylphenyl)methanimidamido 5-methyl-1,2-oxazole-3-carboxylate;
N-[2-(methylsulfanyl)-1,3-benzothiazol-6-yl]thiophene-2-carboxamide;
N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2H-1,3-benzodioxole-5-carboxamide;

- (2E)-3-(2-chlorophenyl)-N-(2-methylbut-3-yn-2-yl)prop-2-enamide;
1-naphthalen-1-yl-3-oxatricyclo[7.4.0.0^{2,7}]trideca-1(13),2,4,6,9,11-hexaen-5-ylthiourea;
3-methyl-N-phenyl-1-benzothiophene-2-carbothioamide;
- 5 5-(2,5-dichlorophenyl)-N-[2-(trifluoromethyl)phenyl]furan-2-carboxamide;
3-(5-methyl-1,2-oxazol-3-yl)-5-(thiophen-2-yl)-1,2,4-oxadiazole;
N-(1H-indazol-3-yl)-3-methoxybenzamide;
2-(4-tert-butylphenyl)-5-[(propane-1-sulfonyl)methyl]-1,3,4-oxadiazole;
1-[2-(4-chlorophenoxy)methyl]-4-methyl-1,3-thiazol-5-yl]ethan-1-one;
- 10 (4-methanesulfonamidophenyl)methanimidamido N-(4-methylphenyl)carbamate;
N-phenyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine hydrochloride;
7-nitro-N-(2-phenylethyl)-1H-indole-2-carboxamide;
2-{[(2E)-4-(pyridin-2-ylsulfanyl)but-2-en-1-yl]sulfanyl}pyridine;
4-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-2-[(3-nitropyridin-2-yl)sulfanyl]pyrimidine;
- 15 4-(4-chlorophenyl)-2-[(4-methoxyphenyl)methyl]-1,3-thiazole;
(3Z)-3-[[5-(thiophen-2-yl)thiophen-2-yl]methylidene]-2,3-dihydro-1H-indol-2-one;
N-(4-bromo-2,5-difluorophenyl)-2,3-dimethylbenzamide;
sodium N-phenyl(phenylamino)carboximidate;
2-(benzylsulfanyl)-N-(2,3-dihydro-1H-inden-2-yl)acetamide;
- 20 (5Z)-5-[(5-methylfuran-2-yl)methylidene]-3-phenyl-1,3-thiazolidine-2,4-dione;
N-{4-[(3-chlorophenyl)carbonyl]phenyl}thiophene-2-carboxamide;
N-[(3-chlorophenyl)methyl]-5-(methylsulfanyl)-1,3,4-thiadiazol-2-amine;
(E)-2-(phenylamino)-3-(phenylimino)guanidine;
(2Z)-3-methyl-2-[2-(3-methyl-2,3-dihydro-1,3-benzoxazol-2-ylidene)hydrazin-1-ylidene]-2,3-dihydro-1,3-benzoxazole;
- 25 3-[2-(2H-1,4-benzothiazin-3-yl)hydrazin-1-yl]-2H-1,4-benzothiazine;
3-(3,4-dimethyl-1,2-oxazol-5-yl)-1-[4-(dimethylamino)-3,5-difluorophenyl]carbonylurea;
(3Z)-3-[2-(2,5-difluorophenyl)hydrazin-1-ylidene]piperidin-2-one;
- 30 N'-[(E)-[1-(1-benzofuran-2-yl)ethylidene]amino](methylsulfanyl)methanimidamide;
(2Z)-3-(9H-fluoren-2-ylcarbonyl)prop-2-enoic acid;
4-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)diazen-1-yl]-N,N-diethylaniline;

- 4,5-dichloro-N-(3-chloro-4-fluorophenyl)-1,2-thiazole-3-carboxamide;
5-[4-(4-methoxyphenoxy)phenyl]-1H-pyrazole;
1-cyclohexyl-3-[(Z)-(1H-pyrazol-3-ylmethylidene)amino]thiourea;
[5-(4-chlorophenyl)-3-methyl-2-sulfanylidene-1,3,4-thiadiazinan-6-ylidene]amino 5-
5 tert-butylthiophene-2-carboxylate;
N-(2-phenylethyl)benzenecarbothioamide;
5-amino-3-methyl-2-N-phenylthiophene-2,4-dicarboxamide;
3-amino-5-(thiophen-3-yl)thiophene-2-carboxamide;
(2E)-2-[[4-(trifluoromethoxy)phenyl]imino]-3,4-dihydro-2H-1,3-benzoxazin-4-one;
10 3-hydroxy-9H-xanthen-9-one;
4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol;
(3-chlorophenyl)methanimidamido 6-(2,2,2-trifluoroethoxy)pyridine-3-carboxylate;
5-phenyl-3-(pyrrolidin-1-yl)-1,2-thiazole-4-carbonitrile;
7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one;
15 2-(4-fluorophenyl)-2H,3H,5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrimidin-3-one;
(4-chlorophenyl)methanimidamido 2,6-difluorobenzoate;
2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one;
6,7-dimethoxy-2-phenylquinoxaline;
6-methoxy-3-phenyl-[1,2,4]triazolo[4,3-a]pyridazine;
20 5-[4-(furan-2-ylcarbonyl)piperazin-1-yl]-3-(thiophen-2-yl)-1,2,4-thiadiazole;
(E)-{1-[2-(4-chlorophenoxymethyl)-1,3-thiazol-4-yl]ethylidene} amino benzoate;
N-[(2-chloro-6-fluorophenyl)carbonyl]-N'-(4-methylpyridin-2-yl)ethanediamide;
(E)-hydroxy[1-(2-phenyl-1,3-thiazol-4-yl)ethylidene]amine;
ethyl 1-[[4-(trifluoromethoxy)phenyl]carbonyl]piperidine-4-carboxylate;
25 3-(3-methyl-1H-indol-1-yl)-N-[4-(morpholin-4-yl)phenyl]propanamide;
6,8-dimethyl-1-methylidene-2-(4-methylphenyl)-1,4-dihydronaphthalene;
N'-[(2-methyl-1,3-thiazol-4-yl)methoxy]-4-(trifluoromethyl)benzene-1-
carboximidamide;
1-[4-(benzyloxy)phenyl]-3-[(3-cyanopyridin-2-yl)amino]urea;
30 2-phenylimidazo[1,2-a]pyridine;
3-(morpholin-4-yl)-5-[4-(trifluoromethyl)phenyl]-1,2-thiazole-4-carbonitrile;
N-(2-chlorophenyl)-2-[(3-cyano-6-acetylpyridin-2-yl)sulfanyl]acetamide;

- 3-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-5-methyl-1,2-oxazole;
 N-(3-bromo-5-methylpyridin-2-yl)-4-ethylbenzamide;
 2-(5-methyl-1,2-oxazol-3-yl)-5-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazole;
 (E)-[1-(3-methyl-1-benzothiophen-2-yl)ethylidene]amino N-phenylcarbamate;
 5 N-(2,3-dihydro-1H-inden-2-yl)-3-(3-methyl-1H-indol-1-yl)propanamide;
 1,3-dimethanesulfonyl-2,3-dihydro-1H-1,3-benzodiazole;
 methyl 2-[5-methyl-2-(thiophene-2-amido)-1,3-thiazol-4-yl]acetate;
 4-[(5-[(4-chlorophenyl)sulfanyl]methyl)furan-2-yl]carbonylmorpholine;
 2-oxo-2-phenylethyl 2,3-dimethoxybenzoate;
 10 N-(4-chlorophenyl)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide;
 (2,4-dichlorophenyl)methyl N-[(2-fluorophenyl)carbonyl]carbamate;
 2-[(4-chlorophenyl)carbonyl]-1-benzofuran;
 4-chlorophenyl 2,3-dihydro-1-benzofuran-5-carboxylate;
 2-[4-(dimethylamino)phenyl]-1,2,3,4-tetrahydroquinolin-4-one;
 15 [6-(ethylsulfanyl)pyridin-3-yl]methanimidamido thiophene-2-carboxylate;
 N-[(6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl]-6-[2-(4-
 methylpiperazin-1-yl)pyridin-4-yl]-1-(propan-2-yl)-1H-indazole-4-carboxamide
 (GSK343);
 N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-((1S)-1-
 20 methylpropyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide
 (GSK126);
 N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-
 methyl-1-piperazinyl)-3-pyridinyl]-1H-indazole-4-carboxamide (GSK926)
- 25 5. The pharmaceutical composition of any of the preceding claims, wherein said
 inhibitor is (-)-1-[(1R,4R,5S)-3-(Hydroxymethyl)-4,5-dihydroxy-2-cyclopenten-1-
 yl]4-aminoimidazo[4,5-c]pyridine hydrochloride (DZNep; 3-deazaneplanocin A).
6. The pharmaceutical composition according to claim 1 or 2 or 3, wherein said inhibitor
 30 is an EZH2-binding protein.

7. The pharmaceutical composition according to claim 6, wherein said EZH2-binding protein is an antibody or fragment thereof.
8. The pharmaceutical composition according to claim 1 or 2 or 3, wherein said inhibitor is a nucleic acid molecule or conjugate thereof.
9. The pharmaceutical composition according to claim 8, wherein said nucleic acid molecule is a small interfering RNA.
10. 10. The pharmaceutical composition according to claim 1 or 2 or 3, wherein said enhancer is interferon-gamma (IFN- γ).
11. The pharmaceutical composition according to claim 1 or 2 or 3, wherein said inhibitor is DZNep and said enhancer is IFN- γ .
12. The pharmaceutical composition according to any of the preceding claims for use in therapy.
13. A method of treating a patient having cancer comprising administration of the pharmaceutical composition as defined in any one of claims 1-12.
14. The method of claim 13, wherein the pharmaceutical composition is as defined in claim 11.
15. 15. The method according to any one of claims 12 to 14 wherein said inhibitor is used in amount of less than 3 mg/kg, or less than 2mg/kg, or less than 1 mg/kg, or less than 0.8 mg/kg, or less than 0.5 mg/kg, or less than 0.2 mg/kg, or between about 0.1 mg/kg to about 3 mg/kg.
16. 16. The method according to any one of claims 12 to 15, wherein said enhancer is used in an amount of less than 5×10^6 IU/kg, or less than 10^6 IU/kg, or less than 5×10^5 IU/kg,

or less than 2×10^5 IU/kg, or in an amount of between about 1×10^5 IU/kg to about 10^6 IU/kg.

17. The method according to any one of the preceding claims, wherein cancer is a metastatic cancer.
18. The method according to claim 17, wherein said metastatic cancer is a prostate cancer.
19. The method according to claim 13 to 16, wherein cancer is selected from a group comprising liver, ovarian, lung, acute lymphoblastic leukemia, breast particularly luminal B breast, bladder, or lymphoma mantle-cell cancer.
20. The method according to any one of claims 12 to 19, wherein said patient is characterized by an increased level of EZH2 in a tumor sample and a decreased level of IFNGR1 in a tumor sample.
21. A method for determining susceptibility of a patient suffering from cancer to a treatment with a pharmaceutical composition as defined in any one of claims 1 to 11, wherein the method comprises:
- comparing a first level of EZH2 selected from the group consisting of EZH2 mRNA level in a tumor sample, EZH2 cDNA level made from mRNA from said tumor sample, and EZH2 protein level from said tumor sample, with a second level of EZH2 selected from the group consisting of EZH2 mRNA level from a non-tumor sample from said patient, EZH2 cDNA level made from mRNA from said non-tumor sample, and EZH2 protein level from said non-tumor sample;
 - comparing a first level of IFNGR1 selected from the group consisting of IFNGR1 mRNA level from said tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1 selected from the group consisting of IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from

mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample; and


- c. wherein a patient characterized by an increased level of EZH2 in said tumor sample and a decreased level of IFNGR1 in said tumor sample is susceptible to a treatment with said pharmaceutical composition.

- 5
22. A method for treating cancer in a patient with a difference in the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein in a tumor sample, and the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein and IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein from a non-tumor sample, wherein the level of EZH2 mRNA, and/or EZH2 cDNA, and/or EZH2 protein are at least 2-fold higher in the tumor sample and the IFNGR1 mRNA, and/or IFNGR1 cDNA, and/or IFNGR1 protein level is at least 2-fold lower in the tumor sample, wherein the method comprises administration of a pharmaceutical composition according to any one of claims 1-12 to the patient.
- 10
- 15
23. The method of claim 21 or claim 22, wherein cancer is selected from a group comprising prostate, liver, ovarian, lung, acute lymphoblastic leukemia, breast particularly luminal B breast, bladder, or lymphoma mantle-cell.
- 20
24. The method of claim 21 or claim 22, wherein the first level of EZH2 protein from said tumor sample and the second level of EZH2 protein from said non-tumor sample, and wherein a first level of IFNGR1 protein from said tumor sample with the level of IFNGR1 protein from said non-tumor sample is examined by immunohistochemistry.
- 25
25. The method of claim 21 or claim 22, wherein the level of EZH2 expression from said tumor sample and from said non-tumor sample, and wherein the level of IFNGR1 expression from said tumor sample and from said non-tumor sample is examined by q-PCR, wherein q-PCR comprises selecting primers comprising SEQ ID Nos 1 to 4.
- 30

26. A method for determining susceptibility of a patient suffering from advanced prostate cancer to a treatment with a pharmaceutical composition as defined in any one of claims 1 to 11, wherein the method comprises:
- 5 a. comparing a first level of IFNGR1 selected from the group consisting of IFNGR1 mRNA level in a tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1 selected from the group consisting of IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample; and
- 10 b. wherein a patient characterized by a decreased level of IFNGR1 in said tumor sample is susceptible to a treatment with said pharmaceutical composition.
27. A method for determining susceptibility of a patient suffering from breast cancer to a treatment with a pharmaceutical composition as defined in any one of claims 1 to 11, wherein the method comprises:
- 15 a. comparing a first level of IFNGR1 selected from the group consisting of IFNGR1 mRNA level in a tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1 selected from the group consisting of IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample;
- 20 b. wherein a patient suffering from basal breast cancer is characterized by an increased level of INFGR1 in said tumor sample is not susceptible to a treatment with said pharmaceutical composition ; and
- 25 c. wherein a patient suffering from luminal breast cancer is characterized by a decreased level of INFGR1 in said tumor sample is susceptible to a treatment with said pharmaceutical composition.
- 30 28. A method for making a prognosis with respect to the clinical outcome of a patient suffering from cancer comprising:

- 5 a. comparing a first level of EZH2 selected from the group consisting of EZH2 mRNA level in a tumor sample, EZH2 cDNA level made from mRNA from said tumor sample, and EZH2 protein level from said tumor sample, with a second level of EZH2 selected from the group consisting of EZH2 mRNA level from a non-tumor sample from said patient, EZH2 cDNA level made from mRNA from said non-tumor sample, and EZH2 protein level from said non-tumor sample;
- 10 b. comparing a first level of IFNGR1 selected from the group consisting of IFNGR1 mRNA level from said tumor sample, IFNGR1 cDNA level made from mRNA from said tumor sample, and IFNGR1 protein level from said tumor sample with the level of IFNGR1 selected from the group consisting of IFNGR1 mRNA level from a non-tumor sample from said patient, IFNGR1 cDNA level made from mRNA from said non-tumor sample, and IFNGR1 protein level from said non-tumor sample; and
- 15 c. making a prognosis with respect to the clinical outcome of a patient suffering from cancer.
29. The method as claimed in claim 28, wherein said clinical outcome indicates the susceptibility to treatment with said pharmaceutical composition as claimed in any one of claims 1-11.
- 20 30. The method as claimed in claim 28 or 29, wherein the cancer is selected from a group comprising prostate, liver, ovarian, lung, particularly small cell lung, acute lymphoblastic leukemia, breast particularly luminal B breast, bladder, or lymphoma mantle-cell cancer.
- 25

FIG. 1



B

Top Canonical Pathways	P-Value	Ratio
Interferon Signaling	3.13E ⁻¹¹	13/34 (0.382)
Activation of IRF by Cytosolic PPR	5.35E ⁻⁰⁶	11/64 (0.172)
PPR Recognition of Bacteria and Viruses	5.5E ⁻⁰⁵	12/77 (0.156)
Hepatic Stellate Cell Activation	6.13E ⁻⁰⁵	15/140 (0.107)
Aryl Hydrocarbon Receptor Signaling	4.94E ⁻⁰⁴	13/139 (0.094)

Representative IFN genes

<i>MX1</i>
<i>OAS1</i>
<i>IFIH1</i>
<i>IFI6</i>
<i>XAF1</i>
<i>IFIT3</i>
<i>IFI44</i>
<i>CXCL10</i>
<i>IFIT1</i>
<i>IFIT2</i>
<i>OAS1</i>
<i>ISG15</i>
<i>IRF9</i>
<i>TNFSF10</i>
<i>IFI16</i>
<i>PSMB9</i>
<i>ISG20</i>
<i>GBP1</i>
<i>LAMP3</i>
<i>IRF7</i>
<i>OAS3</i>
<i>IFITM2</i>
<i>TAP1</i>
<i>IFNGR1</i>

C




FIG. 1 (Cont'd)





FIG. 2

A



B






FIG. 2



D



E




FIG. 2 (Cont'd)





FIG. 3




FIG. 3 (cont'd)




FIG. 4




FIG. 4 (Cont'd)




FIG. 4 (cont'd)





FIG. 4 (Cont'd)




FIG. 5







FIG. 5 (Cont'd)

C



D



E





FIG. 5 (cont'd)

F



G




FIG. 5 (cont'd)





FIG. 6




FIG. 6 (Cont'd)




FIG. 7




FIG. 7 (Cont'd)





FIG. 8






FIG. 9

A



B





FIG. 9 (Cont'd)

C





FIG. 9 (Cont'd)

D



E




FIG. 10





FIG. 10 (Cont'd)





FIG. 11

A

Analysis Type by Cancer	<i>EZH2</i>		<i>IFNGR1</i>	
	Cancer vs. Normal		Cancer vs. Normal	
Bladder Cancer	6			
Brain and CNS Cancer	11	1	8	2
Breast Cancer	11	2	1	7
Cervical Cancer	4		3	
Colorectal Cancer	20			7
Esophageal Cancer	2	1	2	
Gastric Cancer	3		2	
Head and Neck Cancer	4	1	3	
Kidney Cancer	6	1	5	1
Leukemia	5	6	2	14
Liver Cancer	4		2	
Lung Cancer	16		1	14
Lymphoma	4		2	1
Melanoma				
Myeloma	1		1	1
Other Cancer	3	7	3	
Ovarian Cancer	6			5
Pancreatic Cancer	2		2	
Prostate Cancer	6			1
Sarcoma	11		3	4
Significant Unique Analyses	128	19	49	54
Total Unique Analyses	393		407	

P-value < 0.001,
Threshold 1.5 folds

FIG. 11 (Cont'd)

B




FIG. 12




FIG. 12 (Cont'd)




FIG. 12 (Cont'd)




FIG. 13




FIG. 14





FIG. 14 (Cont'd)

M



F





FIG. 14 (Cont'd)



INTERNATIONAL SEARCH REPORT

International application No.
PCT/SG2013/000490

A. CLASSIFICATION OF SUBJECT MATTER

A61K 38/21 (2006.01) C07K 14/555 (2006.01) C07K 14/715 (2006.01) A61K 31/52 (2006.01) A61P 35/00 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, MEDLINE, HCA, BIOSIS (DZNep, deazaneplanocin, interferon, cancer, EZH2, enhancer of zeste 2, IFNGR1)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	



Further documents are listed in the continuation of Box C



See patent family annex

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
7 February 2014Date of mailing of the international search report
07 February 2014

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
Email address: pct@ipaaustralia.gov.au
Facsimile No.: +61 2 6283 7999

Authorised officer

Neal Dalton
AUSTRALIAN PATENT OFFICE
(ISO 9001 Quality Certified Service)
Telephone No. 0399359615

INTERNATIONAL SEARCH REPORT

International application No.

C (Continuation).

DOCUMENTS CONSIDERED TO BE RELEVANT

PCT/SG2013/000490

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X L	WO 2012/051492 A2 (UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC) 19 April 2012 (see abstract, page 6 lines 1-6, page 9 lines 3-11 and claims 18-22, 28-31, page 19 lines 28-29) Lack of unity	1-5, 10-12
X	WO 2009/105513 A2 (GILEAD SCIENCES, INC.) 27 August 2009 (see abstract, page 17 line 3, page 23 lines 24-34, page 29 lines 11-25, page 30 lines 23-24, page 31 lines 10 and 12)	1-5, 10-20
X	WO 2009/143603 A1 (GENOMEDX BIOSCIENCES, INC.) 03 December 2009 (see page 221 table 6, page 226 line 41, and page 228 line 52, claim 1)	28, 30

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:
 - a. (means)
 - on paper
 - in electronic form
 - b. (time)
 - in the international application as filed
 - together with the international application in electronic form
 - subsequently to this Authority for the purposes of search
2. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

A sequence listing was filed but it was not used for the purposes of this search and opinion.

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
the subject matter listed in Rule 39 on which, under Article 17(2)(a)(i), an international search is not required to be carried out, including
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Supplemental Box for Details

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-5, 10-30
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

Supplemental Box**Continuation of: Box III**

This International Application does not comply with the requirements of unity of invention because it does not relate to one invention or to a group of inventions so linked as to form a single general inventive concept.

This Authority has found that there are different inventions based on the following features that separate the claims into distinct groups:

Invention 1: Claims 1-4, 10, 12-13, 15-27 (all in part) and 5, 11, 14 (in full) are directed to pharmaceutical compositions comprising an EZH2 inhibitor and an enhancer of interferon-gamma. The feature of the EZH2 inhibitor being DZNep is specific to this group of claims.

Inventions 2-173: Claims 1-4, 10, 12-13, 15-27 (all in part) are directed to pharmaceutical compositions comprising an EZH2 inhibitor and an enhancer of interferon-gamma. **Each** of the other (172) EZH2 inhibitors recited in claims 1, 6 and 8 is considered to be a group defining feature.

Invention 174: Claims 28-30 (in full) are directed to methods of making a prognosis with respect to the clinical outcome of a patient suffering from cancer. This feature is specific to this group of claims.

PCT Rule 13.2, first sentence, states that unity of invention is only fulfilled when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features. PCT Rule 13.2, second sentence, defines a special technical feature as a feature which makes a contribution over the prior art.

When there is no special technical feature common to all the claimed inventions there is no unity of invention.

In the above groups of claims, the identified features may have the potential to make a contribution over the prior art but are not common to all the claimed inventions and therefore cannot provide the required technical relationship. Therefore there is no special technical feature common to all the claimed inventions and the requirements for unity of invention are consequently not satisfied *a priori*.

Furthermore, the only feature common to claimed inventions 1-173 and which provides a technical relationship among them is a pharmaceutical composition comprising an EZH2 inhibitor and an enhancer of interferon-gamma. However this feature does not make a contribution over the prior art because it is disclosed in:

D1: WO 2012/051492 A2 (UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.) 19 April 2012.

Specifically, D1 is directed to compounds that inhibit EZH2 and their use in inhibiting HIV latency (See abstract, page 6 lines 1-6, page 9 line 11). D1 discloses compositions comprising EZH2 inhibitors in combination with other anti-HIV agents (see page 9 lines 3-6), including gamma interferon (see page 19 lines 28-29 and claims 20-22, 28-31).

Therefore in the light of this document this common feature cannot be a special technical feature. Therefore there is no special technical feature common to all the claimed inventions and the requirements for unity of invention are consequently not satisfied *a posteriori*.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SG2013/000490

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2012/051492 A2	19 Apr 2012	None	
WO 2009/105513 A2	27 Aug 2009	AU 2009215547 A1	27 Aug 2009
		CA 2715885 A1	27 Aug 2009
		CN 102015739 A	13 Apr 2011
		EP 2245037 A2	03 Nov 2010
		EP 2308885 A2	13 Apr 2011
		JP 2011514336 A	06 May 2011
		KR 20100127242 A	03 Dec 2010
		NZ 587464 A	27 Jul 2012
		TW 200948823 A	01 Dec 2009
		US 2009232768 A1	17 Sep 2009
		US 8163718 B2	24 Apr 2012
		WO 2009105513 A2	27 Aug 2009
WO 2009/143603 A1	03 Dec 2009	AU 2009253675 A2	27 Jan 2011
		CA 2725978 A1	03 Dec 2009
		EP 2291553 A1	09 Mar 2011
		US 2011136683 A1	09 Jun 2011
		WO 2009143603 A1	03 Dec 2009

End of Annex

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)